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Abbreviations  
AU  Agatston units 
AP  Angina Pectoris 
CAC  Coronary artery calcium 
CAD  Coronary artery disease 
CT  Computed tomography 
DanRisk  The Danish Risk Score study  
ECG  Electrocardiogram 
HR  Hazard Ratio 
hsTn  High sensitive troponins 
ICD-10  International classification of disease with 10th revision 
IQR  Interquartile range 
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English summary
 
Patients with chest pain of unknown aetiology are a challenge to the emergency departments 
and the cardiology departments. In spite of great advances within the cardiology field over the 
last decades, the knowledge of patients with non-specific chest pain (NSCP) and their prognosis is limited. In this thesis, we wanted to describe this patient population, their characteristics, risk 
stratification and prognosis for a year of follow-up.  
In study I, we examined the overall prognosis for NSCP patients before and after high sensitive 
troponins implementation and compared them to other diagnostic groups as myocardial 
infarction (MI), other heart-related conditions and stable angina pectoris in a population-based 
study. Our findings showed that the all-cause one-year mortality and risk of a cardiac related 
event (myocardial infarction, ventricular arrhythmia, and cardiac arrest) for NSCP was 
favourable, especially compared to the MI group. The all-cause one year mortality was 
corresponding to the general population. 
In study II, we aimed to investigate risk factors characterising NSCP patients with a clinical 
endpoint and their prognosis during one year of follow-up. We conducted a prospective cohort 
study that included NSCP patients and gathered data prospectively.  In this study, we 
demonstrated that NSCP patients have a good prognosis, with few cardiac-related events and 
one-year all-cause mortality similar to the general population. The risk factors identified were 
gender, Charlson score >=1, previous known coronary artery disease, hypertension, 
hypercholesterolemia, diabetes and use of statins (cholesterol lowering medication). However, 
the few events occurring in this study limits the statistical statements inference.   
In study III, we investigated the role of non-contrast cardiac computer tomography in NSCP 
patients and determined whether there was a relationship between coronary artery calcium and 
clinical endpoints occurring during one year. This was a double-blinded prospective cohort 
study.  The study population from the Danish Risk score (DanRisk) study represented the 
asymptomatic general population for comparison. We found no significant difference in the 
prevalence of coronary artery calcium or occurrence of clinical endpoints for the NSCP 
population compared to the DanRisk population. We could not make a definite conclusion based 
on the few events occurring during one-year follow-up.  
In general, all three studies have concluded that NSCP patients have a good prognosis compared 
to the general population and patients with MI. The all-cause mortality for NSCP was 
comparable with the age and gender-adjusted general population. The occurrence of cardiac-
related endpoints were few and associated with risk factors such as male gender, Charlson score 
>=1, previous coronary artery disease, hypertension, hypercholesterolemia, diabetes and use of 
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statins. The indication for cardiac computed tomography was not more significant for NSCP 
patients than for the asymptomatic DanRisk general population.   
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Dansk resumé
 
Patienter med brystsmerter af ukendt ætiologi udgør en udfordring i vores akutmodtagelser 
samt kardiologiske afdelinger.  Til trods for den udvikling, der har fundet sted indenfor det 
kardiologiske felt de sidste årtier, er den viden, der eksisterer om patienter med uspecifikke 
brystsmerter (NSCP), begrænset. I denne afhandling ønskede vi at beskrive patientgruppen af 
NSCP patienter, deres karakteristika, risikostratificering samt prognose for ét år.  
Det første studie var et registerbaseret studie, der undersøgte den overordnede prognose for 
NSCP patienter før og efter, at højsensitive troponiner blev implementeret og sammenlignede 
dem med andre diagnosegrupper som myokardieinfarkter (MI), andre hjerterelaterede tilstande 
og stabil angina pectoris.  Vi påviste, at den overordnede dødelighed og risiko for hjertekar-
relaterede hændelser var lav hos NSCP patienter, især sammenholdt med MI patienter. Den 
overordnede etårs mortalitet var sammenlignelig med den mortalitet, vi fandt hos den alders- og 
kønsjusterede baggrundsbefolkning.  
I det andet studie, studerede vi risikofaktorer, der karakteriserede NSCP patienter samt deres 
etårs prognose efter en akut henvendelse for brystsmerter, herunder omfanget af patienter, der 
blev diagnosticeret med hjertekarsygdom i løbet af et års opfølgningstid, samt risikofaktorer der 
kunne identificere disse patienter ved første kontakt.  Studiet blev udført som et prospektivt 
kohorte studie. Dette studie viste, at NSCP patienter havde en favorabel prognose med få 
hjerterelaterede hændelser.  Den totale mortalitet var sammenlignelig med 
baggrundsbefolkningen. De identificerede risikofaktorer var køn, Charlson score >=1, tidligere 
kendt hjertekarsygdom, hypertension, hypercholesterolæmi, diabetes samt statin 
(cholesterolsænkende medicin) forbrug. De få hændelser som fandt sted betød dog, at vi ikke 
kan drage en sikker konklusion vedrørende disse risikofaktorers prædiktive værdi.  
I det tredje studie, undersøgte vi non-kontrast hjerte Computer Tomografi og dennes rolle i 
risikostratificeringen af NSCP patienter, herunder om der var en association mellem 
koronararterie calcium og de kliniske hændelser, der fandt sted under etårs opfølgning. Studiet 
blev gennemført som et dobbeltblindet prospektivt kohorte studie. DanRisk studiepopulation 
repræsenterede den asymptomatiske baggrundsbefolkning og blev brugt til sammenligning med 
vores egen studiepopulation. Ingen signifikante forskelle blev fundet i tilstedeværelsen af 
koronararterie calcium eller forekomsten af kliniske hændelser mellem NSCP og DanRisk. Vi 
kunne ikke konkludere på, om der var en sammenhæng mellem forhøjet koronararterie calcium 
og risikoen for en hjertekar-relaterede hændelse på baggrund af de få hændelser, der fandt sted 
under opfølgningen.  
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Den overordnede konklusion i dette studie er, at prognosen for NSCP patienter er favorabel 
sammenlignet med baggrundsbefolkningen og MI patienter. Den generelle dødelighed var 
sammenlignelig med den køns- og aldersjusterede baggrundsbefolkning. De hjertekar-
relaterede hændelser som forekom i løbet af opfølgningstiden var få og var associeret med 
risikofaktorerne mandligt køn, Charlson score >=1, tidligere kendt koronararteriesygdom, 
hypertension, hypercholesterolæmi, diabetes samt statin forbrug. Hjerte Computer Tomografi 
var ikke mere indiceret hos NSCP patienter end for den asymptomatiske baggrundsbefolkning.       
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Prologue 
 
Imagine this: the setting is an emergency department or cardiology department. You are the physician 
on call. The department is overcrowded. The time is 3 p.m. Still, three patients with chest pain to 
assess. The electrocardiograms are normal. The blood test likewise, including the high sensitive 
troponins measurements. Your clinical judgment tells you these are low-risk patients for cardiac-
related chest pain. You do not suspect another diagnosis, which requires treatment. You send them 
home without subsequent work up. 
 “I wonder how it will go them.”  you reflect while you dictate the discharge note and label it with the 
discharge diagnosis “Chest pain” or “Observation for myocardial infarction”.  Will they come back 
with a myocardial infarction tomorrow? Possibly in six months?  Could I have reassured them that 
there was no higher risk for such an event for these patients than anyone else? Are the new sensitive 
troponins so sensitive that they detect everything that should be caught? Can I rely on my clinical 
judgment that they do not need further follow-up? Are the traditional risk factor assessments enough 
or should they have been investigated with some of the advanced devices available next to the 
emergency department? What about a fast computer tomography scan for calcification in the coronary 
vessels? Takes just 5 minutes on the way home, anyway.  
I have found my-self in this situation several times and I share your concerns and questions. I would 
like to search for the answers in this Ph.D., so that we in the future can add a little more knowledge to 
the discharge situation and counseling. This thesis will provide you with some of the answers.  
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Background 
 
Cardiovascular disease is a leading cause of death among women and men in Europe. 
Cardiovascular disease causes 51% of all deaths in women and 42% in men, respectively (1, 2). 
In Denmark, it is only to be exceeded by cancer-related deaths (1). A subgroup of cardiovascular 
diseases is coronary artery disease (CAD). The statistics show a decreasing mortality rate of CAD 
while the hospitalisation and prevalence of CAD are increasing (3).  
The acute presentation of CAD is acute myocardial infarction (MI). The handling of MI has gone 
through a remarkable development. Just a decade ago the treatment for acute ST-elevation MI 
was fibrinolysis (4, 5) and before that virtually no causal treatment existed. The DANAMI II 
study established the role of an early invasive strategy with primary percutaneous coronary 
intervention in ST- elevations MI patients (6). The role of revascularisation in non- ST-segment 
elevation MI patients was furthermore secured and studies confirmed the improvement in long-
term mortality with revascularisation strategies (7, 8).    
High sensitive troponins 
In the 1960s Lactate dehydrogenase was the preferred biomarker for MI (9). Almost 
concurrently the creatinine kinase was used for the same purpose (10). Just 20 years ago the 
evaluation of MI in the emergency departments consisted of history, electrocardiogram (ECG) 
and blood test; the golden standard being creatinine kinase MB (11, 12). Troponin, a protein 
complex that serves as a biomarker for cardiac cell death (13), was only safe to use as an 
exclusion tool for AMI if the diagnosis was made more than 6 hours from the time of emergency 
department presentation (14). From the year 2000 troponin was included in the definition of MI 
(15).  
Since then several generations of troponin assays have been developed leading to high sensitive 
troponins (hsTn) (16, 17).  The newest assays show very high negative predictive values above 
99% when the cut-off is set at undetectable values (18, 19).  
Figure 1 illustrates the three studies in this thesis in context with the progress of cardiac marker 
and treatment strategies.  
17 
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Figure 1 
The timeline depicts the course for novel cardiac markers, treatment strategies for MI and the course of the studies in this 
thesis. LDH: Lactate dehydrogenase, CK: creatinine kinase, CK-MB: Creatinine Kinase MB, PCI: percutaneous coronary 
intervention. 
 
Chest pain  
Chest pain is the cardinal symptom of MI. Only 15-20% of patients with chest pain turn out to 
have an acute MI (18, 20, 21), while about 50% have chest pain of undetermined cause (22). 
Chest pain is a symptom that gives rise of suspicion to many differential diagnoses from the 
more benign disorders with low health impact to the acute and fatal conditions.  
According to the consensus document, the definition of MI is based on elevated troponin above 
the 99th percentile and ischemic symptoms or ECG changes concordant with myocardial 
ischemia (23). MI was defined as myocardial necrosis, which is myocardial cell death that causes 
an increase in troponin together with either ischemia symptoms or ECG changes (23). Increased 
troponin level in the bloodstream indicates myocardial injury, but it does not always mean that 
the myocardial necrosis is present or caused by myocardial ischemia. Other causes of troponin 
rise can be due to cardiac surgery, heart failure, and arrhythmia.  Of non-cardiac-related causes, 
renal failure and rhabdomyolysis can be mentioned (24). Hence, the evaluation of acute chest 
pain patients can lead to the diagnosis of MI, other coronary related chest pain as unstable and 
stable angina pectoris (AP), cardiac related chest pain, non-cardiac related chest pain with an 
alternative diagnosis, like pulmonary embolism or gastrointestinal disorders or non-specific 
chest pain (NSCP) when no obvious explanation is found (25).  The possible diagnoses for 
patients with chest pain presentation are listed in Table 1.  
Clinical assessment of chest pain is thus important in the risk stratification of MI. The clinician 
must distinguish between typical cardiac related chest pain and atypical chest pain. Typical 
chest pain is in daily terms referred to as angina and is characterised by retrosternal 
pressure/heaviness, radiation to the left arm, neck or jaw, duration of several minutes or 
persistent (26). Additional symptoms like sweating, nausea, and dyspnoea may also be present. 
Atypical chest pain, on the other hand, is characterised by symptoms like epigastric pain, 
indigestion-like symptoms or the sole presence of dyspnoea (26). Atypical chest pain occurs 
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more in females and in patients with diabetes or chronic renal disease and dementia (27-29). 
When chest pain and concomitant symptoms are worsened by physical effort or relieved by rest 
the likelihood that the chest pain is caused by myocardial ischemia increases.   
 
Low likelihood                                                                                                            High likelihood 
Presentation Atypical       Typical 
ECG - - - -/+ -/+ ++ ++ 
Troponin - - - - + ++ ++ 
Diagnosis Unspecific 
chest pain Non-cardiac chest pain Stable  AP  Unstable  AP Other cardiac chest pain NSTEMI STEMI  
Table 1 
The presentation of chest pain, clinical assessment and diagnosis 
 
The chest pain patient in the emergency departments 
Chest pain complaints account for 6% of emergency departments visits (30, 31). One out of three 
patients with MI diagnosis does not present with typical chest pain symptoms (29).  Even with 
hsTn, it remains a challenge for emergency physicians to be able to identify patients with MI 
when they do not present with typical chest pain. It can lead to delayed and incorrect diagnosis 
and treatment. However, admitting and investigating all patients with a minor suspicion of MI 
means that patients occupy a bed for at least six hours. Newer studies are investigating the 
prognostic implication of a single hsTn measurement below the detection limit as a rule out for 
MI in combination with clinical assessment and non-ischemic ECG (18, 32, 33).  For the moment 
no consensus document or guidelines exist regarding this approach. 
 
Risk assessment 
An important risk stratification tool for patients with CAD is based on the evaluation of 
traditional risk factors like hypertension, hypercholesterolemia, diabetes, lifestyle, obesity, 
smoking and family history. An aggressive prevention and treatment strategy of these risk 
factors is beneficial for the CAD prognosis. Several algorithms have been developed for the 
purpose of risk stratification of CAD patients. The systematic Coronary risk evaluation (SCORE) 
estimates 10-year mortality for cardiovascular disease in Europeans. This risk chart is based on 
the risk factors sex, age, smoking, systolic, blood pressure and cholesterol levels (34). For 
assessment of chest pain in a more acute setting the HEART score was developed taking into 
account history, ECG, age, risk factors including diabetes and troponin (35, 36). The findings by 
Omstedt et al. (37) supported the use of HEART score in NSCP patients. We do, however, know 
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that up to 20% of patients with CAD do not have a traditional risk factor (38) and other forms of 
testing could be useful. 
 
Non-acute assessment of CAD 
Coronary angiography is a reliable test for CAD; however, it is invasive and associated with 
certain risks of complications like hematoma, arrhythmias, coronary artery dissection and 
myocardial infarction (39, 40).  
Even though several possibilities for cardiac testing exist, pros and cons have to be taken into 
consideration with the patient’s pre-test possibility of CAD. Current guidelines for management 
of stable CAD recommends non-invasive testing as the first choice in patients with low to 
intermediate pre-test probability of CAD (41). 
Stress testing with bicycle or treadmill using a 12 lead ECG is the most simple and non-invasive 
test for stable CAD patients with an intermediate pre-test probability (41). The best diagnostic 
information from this test is obtained in patients with normal ECGs and without the use of anti-
ischemic drugs. The interpretation of the results demands an exercise effort where 85% of the 
maximum heart rate is achieved and can be limited by functional problems, which also may 
explain, why this test is outdated today.    
Myocardial perfusion scintigraphy (single photon emission computed tomography and positron 
emission tomography) produces images of regional tracer uptake in rest and in stress, and 
shows hypo-perfusion during stress-induced conditions that is diagnostic for stable CAD (41). 
However, this test is associated with the administration of pharmacological agents and radiation.   
Recent guidelines recommend Cardiac Computed Tomography (CT) angiography as a non-
invasive test for ruling out CAD in patients with intermediate pre-test probability (40-42). This 
test is able to visualise the artery lumen and the narrowing by a contrast agent.  The limitation of 
this test is that it cannot be performed in patients with severe coronary artery calcification, high 
body mass index or irregular rhythm.  
Coronary CT with calcium score (CAC) is a non-invasive diagnostic imaging to assess future 
cardiovascular risk.  Coronary calcium scoring CT has a low radiation risk, with a mean exposure 
of 1 mSv (43), is easy to perform and interpret, cheap and non-invasive. There is a correlation 
between coronary artery calcification and coronary atherosclerosis which is visualised by 
cardiac CT and expressed in Agatston unit (AU) (44). Previous studies have shown that a high 
AU is associated with an increased risk of cardiac event and mortality, while no calcification (0 
AU) has a low risk of cardiac event (45-47). In a symptomatic population without previous 
known CAD, the prevalence of CAC was 79% (48). It has been shown that among an 
asymptomatic background population 44% had coronary calcification and subclinical 
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atherosclerosis (49).  The higher CAC associated with a worse prognosis in an asymptomatic 
population is well established (45, 50). However, diagnostic accuracy is lower in patients with 
previous MI and revascularisations.  Other chest pain groups have also been examined which 
include unstable AP and patients excluded for MI (51, 52).  The role of non-contrast cardiac CT in 
NSCP patients is yet to be investigated.    
Prognosis 
The 10-year mortality rate for MI patients was 59% in 1991  (53).  A decrease in post-discharge 
mortality has been shown since the beginning of the 21st century (54-56). Sarkisian et al 
reported from a patient inclusion from 2010-2011 before hsTn, where a mortality of 39% was 
found in MI patients in Denmark during a median follow up time of 3.2 years (57).  The one-year 
mortality was respectively 27 %, 14% and 5% for non-ST elevation MI, ST elevation MI and 
unstable AP before hsTn definition was introduced around 2013 (58).  HsTn identifies smaller 
MI with a lower mortality rate compared to standard troponin assays and therefore a decrease 
in MI mortality rate can be expected with hsTn (59). 
Few studies have investigated the prognosis for NSCP patients. A small study showed a higher 
frequency of healthcare contact and a higher frequency of drug prescription compared to the 
general population (60). A declining tendency in one-year mortality rate among patients with 
NSCP from 1987-2006 was shown by Fagring et al. (61). Another study investigated NSCP 
patients in the transition period during hsTn implementation and found that 0.8% of NSCP 
patients experienced an adverse event during 30 days follow-up (37). A recently published study 
compared NSCP patients before and after hsTn and showed no significant difference in 
prognosis after hsTn (62). However, the prognosis of NSCP in relation to other higher risk chest 
pain groups has not been elucidated. The number of NSCP patients has increased and is twice as 
large as angina patients (61, 63). Although, that the NSCP patients make up such a substantial 
part of acute chest pain patients seen in the hospitals, very little emphasis has been given to the 
diagnostic work-out or prognosis of these patients.  
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Aims and objectives 
 
The overall aim of this thesis was to describe NSCP patients, their risk of future cardiac-related 
events and prognosis and evaluate clinical risk factors as well as cardiac CT as a risk 
stratification tool.    
Study 1 
The purpose of this population-based study was to describe the prognosis of chest pain patients 
above 18 years old with an acute visit to the emergency departments or cardiology departments 
for chest pain and specifically for NSCP patients before and after hsTn implementation for 
routine clinical use in patients with chest pain.  
The objectives were to 
• describe the change in the proportion of chest pain diagnoses after implementation of 
hsTn. 
• describe one-year mortality in NSCP patients before and after implementation of hsTn 
compared to the general population. 
• describe the prognosis for patients with MI, other heart-related conditions, stable AP and 
NSCP before and after implementation of hsTn – that included all-cause mortality, future 
risk of MI, cardiac arrest and ventricular fibrillation during 12 months follow-up.   
Study 2 
The aim of this clinical prospective cohort study was to describe and identify NSCP patients with 
increased 12 months risk of CAD-related diseases among patients with acute chest pain seen in 
the emergency department or cardiology department where MI was subsequently ruled out.  
The objectives were to 
• determine the rate of cardiac-related events and all-cause mortality among NSCP 
patients during 12 months follow-up 
• identify risk factors among NSCP patients that had a cardiac-related event within 12 
months follow-up     
23 
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Study 3 
The aim of this prospective clinical cohort study was through a double-blinded design to 
determine whether non-contrast CT scan with calcium score could be used to describe the 
association between calcification and cardiac-related events in a NSCP population compared to 
the general population.     
The objectives were to 
• investigate the prevalence of calcification in a NSCP population compared to the DanRisk 
population (49) (general population). 
• describe the rate of cardiac events and the association with CAC within the next 12 
months in NSCP and the DanRisk population.   
• compare the number of clinical events in NSCP patients during 12 months follow-up with 
the events that occurred in the DanRisk population and in the patient group who were 
directly referred for further investigation at index visit.    
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Methods and results
 
The methods and results sections are separated into two sections. Method and results are 
presented for study I in one section and for study II and III in another section. 
 
Data sources in general 
National Patient Register 
The Danish hospitals register all discharge diagnoses and procedures in the Danish National 
Patient Registry. Data from the Danish National Patient Register contains patients’ civil 
registration number, patients’ municipality, identification of hospital ward, date and time of 
activity, diagnoses and surgical procedures. The classification of surgical procedures was from 
1996 in accordance with the Nordic Classification of Surgical Procedures (64). 
We linked this registry with the patient’s civil registration number and received information 
regarding readmissions and procedures. All visits (in-patient and out-patient visits) are 
classified by International Classification of Disease codes with the 10th revision (ICD-10). 
Appendix 1 lists the codes used for study I. MI diagnosis has been validated by clinical 
comparison between the Danish National Patient Registry and the Danish Monitoring Trends 
and Determinants in Cardiovascular Disease registry (65). The latter being a multicentre study 
that registered MI incidence in 21 countries. In this validation, a sensitivity of 97% was shown 
for MI diagnoses (65).  
 
The Danish Civil Registration System  The Danish civil registration system was established in 1968. It contains information on all 
persons, who were alive with a permanent residency in Denmark from 1968 and forward and 
from 1972 for Greenland. All persons are registered by their civil registration number. From the 
Danish Civil Registration System, it is possible to obtain information on vital status, emigration, 
immigration and place of residency (66).  
 
The Odense University Pharmaco-epidemiological Database  
The Odense University Pharmaco-epidemiological Database was established in 1990 and 
covered initially the former Funen County, but from January 2007 was expanded to cover the 
Region of Southern Denmark. All pharmacies in the included area contribute with data to 
Odense University Pharmaco-epidemiological Database. The register contains information on 
civil registration number the dispensed package, the pharmacy, quantity, and date of dispensing. 
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Data from the pharmacies are reported to the Danish Health and Medicines Authority and 
transferred to Odense University Pharmaco-epidemiological Database (67, 68).  
From Odense University Pharmaco-epidemiological Database medication use, defined as 
collected prescriptions for the patient, was identified based on their civil registration number.   
 
Charlson comorbidity index 
The Charlson comorbidity index is one of the most commonly used indexes in confounder 
control for patients’ comorbidity in mortality studies (69) and was updated to ICD-10 (70). 
Comorbidity can be an important confounder for the prognosis for the disease of interest (71). 
The Charlson index was validated in a Danish study conducted in the Region of Northern 
Denmark that compared the Danish National Patient Registry diagnoses with the discharge 
diagnoses and found a positive predictive value of 98% for the overall Charlson conditions (72). 
In our studies, Charlson comorbidity index was based on the primary discharge diagnosis (A 
diagnosis) for all visits (In-patient and out-patient visits).      
 
Method: Study I 
Study design, setting and population                                                         Figure 3: Study I 
This was a prospective register-based cohort study with 
patient inclusion from eight hospitals (Figure 4) in the Region 
of Southern Denmark.  Patients above the age of 18 and with 
acute chest pain were included. In this study, we defined acute 
chest pain as an acute visit to an emergency department or 
cardiology department with a hsTn measurement within 24 
hours of their visit.  
Patient inclusion took place from 1 January 2013 to 31 
December 2013. During this time the assays for troponin 
measurement were changed for all departments to hsTn 
assays.  
Patients were stratified into two cohorts, cohort 1 and cohort 
2, respectively. Cohort 1 comprised patients before the hsTn implementation and cohort 2 after 
the implementation. Each cohort was further stratified into four groups depending on the 
patient's final discharge diagnoses for the entire index visit and the highest level of troponin at 
index visit, with consideration to the 99th percentile for the respective troponin assays.  The 
diagnoses codes are listed in Appendix 1. 
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The four groups defined were a) patients with MI, b) patients with other heart-related 
conditions, c) patients with stable AP and d) patients with NSCP. Patients were followed until 
30th June 2015 or until emigration or clinical endpoints occurred. The results were reported as 
one-year endpoints. The clinical endpoints consisted of all-cause mortality, new MI, cardiac 
arrest and ventricular fibrillation. Cardiac-related endpoints were defined as new MI, cardiac 
arrest, and ventricular fibrillation. Composite endpoints consisted of cardiac-related endpoints 
and all-cause mortality. Each patient could not contribute with more than one endpoint in the 
composite endpoint.   
 
Figure 4  
The hospitals included and the Region of Southern Denmark 
 
Data collection 
The index visit of interest was the first visit to an emergency department or a cardiology 
department during 2013, which could be registered as an acute outpatient visit or acute 
admission. Previous visits to emergency departments or cardiology departments, with the same 
discharge diagnosis up to six months prior to the index visit, was an exclusion criterion as the 
two cohorts were included during two different time periods and this approach made them 
more comparable.  
During the course of an admission, the patient receives a diagnosis for every transfer between 
departments. In this study, we only used the last given primary diagnoses (A diagnosis) during 
the given visit. 
Statistical analysis study I 
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In general, for all three studies, continuous variables were shown as medians and interquartile 
ranges. Normally distributed variables were compared with Student's t-test, while skewed 
distributions were compared with Wilcoxon rank sum test. Categorical variables were presented 
with numbers and percentages and compared with Chi-square test as all our cells included more 
than five counts. P- values <=0.05 were interpreted as statistically significant.   
The mortality in NSCP group was compared with the mortality in the general population in the 
same area. The standardised mortality ratio was calculated adjusted for age and gender. 
One-year outcomes for all groups after hsTn were shown as categorical with frequency and 
percentage and their belonging 95% confidence intervals (CI). Univariate Cox regression was 
used for finding any significant differences between the groups. The Hazard Ratios (HR) were 
depicted unadjusted and adjusted for sex, age and comorbidities to compare the significance 
among the groups with myocardial infarction as the reference groups (=1). The total endpoints 
during total follow-up were depicted as accumulated endpoints.   
Ethics 
The study was registered at The Danish Data Protection Agency (2008-58-0035 nr 1085) and 
approved by the Danish Health Authorities j.nr. 3-3013-862/1/.  
Summary of results: Study I 
In total 5 352 patients were included in this study, of whom 2 151 patients were before hsTn 
implementation and 3 200 from after hsTn.  Figure 5 shows the study inclusion. 
Before hsTn more than half of the cohort was diagnosed with NSCP, one out of four with other 
heart-related conditions, one out of eight with MI and one out of twenty with stable AP.  
After the hsTn implementation, fewer patients were diagnosed with NSCP (8.0 %) and stable AP 
(42.6 %), while more patients were diagnosed with MI (20.9 %) and other heart-related 
conditions (13.9 %). All changes were significant.  
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Figure 5  
Patient inclusion for study I. The prognosis for patients with non-specific chest pain compared to other chest pain 
patients before and after implementation of highly sensitive troponins – a population-based study. Paper I, Figure 1. 
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The mortality rate in NSCP patients did not change, significantly, compared to the before hsTn 
group. A mortality rate of respectively 3.1% (95% CI: 2.2%-4.1%) and 1.9% (95% CI: 1.2%-
2.5%) were found during one-year follow-up before and after hsTn in NSCP patients. Compared 
to the general population the standardised mortality ratio was 1.2 (CI: 0.8-1.7) for NSCP patients 
after hsTn and non-significant. 
The crude one-year prognosis for all four groups showed that NSCP patient and other heart-
related condition patients had the lowest rate of subsequent MI before and after hsTn.  A 
significant decrease in mortality was seen in MI patients from 18.7% (14.3%-23.2%) before 
hsTn to 11.3% (8.7%-14%) after hsTn.  HR adjusted for age, gender, Charlson score,  anti-
diabetic, beta-blockers and cholesterol-lowering medication estimated a 5 times decreased risk 
of future MI in NSCP patients compared to MI group after hsTn. The results are shown in table 2.   
 
 
Table 2 
The risk for death and future MI unadjusted and adjusted for sex, age, Charlson score, anti-diabetic, beta-blockers and 
cholesterol-lowering medications for cohort 2. HR: Hazard ratio, MI: Myocardial infarction, stable AP: stable angina 
pectoris, OHC: other heart-related conditions, NSCP: non-specific chest pain. 
The prognosis for patients with non-specific chest pain compared to other chest pain patients before and after 
implementation of highly sensitive troponins – a population-based study. Paper I, Table 4. 
 
Method: Study II and study III 
Study II: Study design, setting and population     Figure 6: Study II 
This was a prospective study. Danish inhabitants between the 
age of 30 and 70 years with an index acute visit to an 
emergency department or cardiology department in the 
Region of Southern Denmark due to chest pain, and who did 
not have a MI and without obvious cause of their pain were 
included. Patients were included from September 2014 until 
June 2015 and followed until June 2016 or emigration.  
Clinical endpoints were defined as all-cause mortality, cardiac 
death, MI, unstable AP and acute and non-acute 
Groups Unadj HR HR Unadj HR HR Unadj HR HR
MI 1 1 1 1 1 1
SAP 0.3(0.1-0.9) 0.5(0.2-1.3) 0.2(0.1-0.9) 0.3(0.1-3) 0.7(0.2-2.9) 0.8(0.2-3.6)
OHC 0.7(0.5-1.0) 0.6(0.5-0.9) 0.9(0.6-1.2) 0.7(0.5-1.0) 0.2(0.1-0.5) 0.2(0.1-0.5)
NSCP 0.3(0.1-0.2) 0.3(0.2-0.4) 0.3(0.2-0.5) 0.7(0.4-1.1) 0.1(0.04-2.6) 0.2(0.1-0.4)
Composite endpoints Death Future MI
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revascularisations for study II. The cardiac related endpoint was defined as MI, 
revascularisations and unstable AP. Composite endpoint was defined as cardiac-related 
endpoints and all-cause mortality. For study III the endpoints consisted of cardiac death, 
ventricular tachycardia, MI, revascularisations and unstable AP.    
Data collection 
Patients with a hsTn measurement within the last 24 hours from an emergency department or 
cardiology department in any of the six hospitals: Odense University Hospital, Svendborg 
Hospital, Kolding Hospital, Vejle Hospital, Hospital of Southern Jutland- Sonderborg and 
Aabenraa were identified by the Central Biochemical database. Patients with a discharge 
diagnosis code of DR072/DR073/DZ034/DZ035 (unknown causes of chest pain) were afterward 
contacted for a structured phone interview within three days of discharge. 
Information concerning the clinical endpoints was gathered from the Danish National Patient 
Registry and the Danish Civil Registration System at the end of follow up. Both registries are 
described in further details above.   
The questionnaire 
This interview was registered in the electronic questionnaire SurveyXact and was composed of 
questions focusing on the patient’s medical history. The questions were related to the patient’s 
symptoms at index admission, previously known heart conditions, comorbidities, family history, 
previous known CAD, risk factors (smoking, alcohol), and work status. Appendix 2 shows the 
translated questionnaire. 
The interview was conducted by the Ph.D. student and two nurses sharing a full-time position 
for this task. Interviews were mainly conducted during daytime but also during evenings and 
weekends. If no contacts had been established after three phone calls during different times of 
the day and week, no further efforts were made to include the patient. 
Patients were sent written information and informed consent to access  their chart and to use 
the interview, which is required by Danish law. If these were returned with the subject’s 
signature, the patient could be included as a participant.  
Prior to the study, the questionnaire was content validated and tested on patients as well as 
healthcare personnel. The standardised questionnaire was validated for inter-rater validity.  Ten 
questions from the survey regarding the patient's medical history were tested in term of 
comparability between the interviewers. The average agreement was 72% between the 3 
interviewers (range from 55%-100% depending on the question).  
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Chart review including ECG diagnosis 
The aim of the chart review was to obtain information on cholesterol values, ECGs and essential 
clinical features including blood pressure, pulse, respiratory frequency, saturation, temperature 
and echocardiography (Appendix 3). All ECGs were analysed by the first author and validated by a cardiologist. The agreement here was 70 %. The first taken ECG during index admission was 
analysed. An abnormal ECG was compared with previous ECGs. If no action was taken on the 
abnormality according to the chart, it was interpreted as a known abnormality.  
Study III: Study design, setting and population       Figure 7: Study III 
At the end of the telephone interview, we informed the patients 
that we conducted another study, a cardiac CT with CAC 
measurement. All patients with one known risk factor for CAD 
and with no previous invasive or non-invasive cardiac imaging 
testing the last five years were offered participation in the CT 
study.  The patients were mailed written information and 
consent. If these were returned, the Ph.D. student called them 
and gave them information about the study and scheduled an 
appointment for the CT scan. Patients, who came for the scan, had a lipid profile taken if it had not been done at the index 
admission.   
CAC was assessed by a non-contrast cardiac CT scan. The scan was performed in four hospitals 
in the Region of Southern Denmark; Vejle Hospital, Aabenraa Hospital, Svendborg, and Odense 
hospital. CAC was assessed by summing the scores from all foci in the coronary arteries and 
expressed in AU. The DanRisk study population was used as a representative asymptomatic 
general population for comparison (49).  
This study was conducted double-blinded. The patients were not informed of the result until one 
year later when they received a letter if their CT scan revealed no or little calcification (CAC<400 
AU). Patients with moderate to high calcification (CAC>400 AU) received a letter and a phone 
call from the Ph.D. student to answer further questions. 
The CAC was assessed by radiographers, who were trained by cardiologists. The CAC was 
reanalysed by the Ph.D. student. The correlation of the CAC analyses between the Ph.D. student 
and the radiographers was 99%.  
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Statistical analyses study II and III 
Sample size calculations were conducted for both studies and described in paper II and III, 
respectively. 
Study II: Univariate Cox regression analysis was used to analyse HR for the association between 
risk factors and endpoints.  Variables without known values, like information of cholesterol 
levels, were analysed as missing values.  
All endpoints were reported for one-year follow-up in frequencies and percentages of total 
cohort.  Endpoints were furthermore reported as a composite endpoint accounting for one event 
for each patient which was the first adverse event that occurred during the follow-up period.     
In study III, age was presented as mean to be able to compare with DanRisk that consisted of 50-
years-old and 60-year-olds. CAC was a continuous not-normally distributed variabel and 
reported as medians with interquartile range (IQR). 
Endpoints were reported for a one year follow-up period. Clinical endpoints were reported in 
percentages.  Prevalence of CAC (CAC>0) was reported with percentage and compared in 2x2 
tables with Chi-square test. Multiple logistic regression with adjustment for age, sex, 
hypercholesterolemia, family history and smoking was used to compare prevalence of CAC in 
NSCP with the DanRisk population.    
Ethics 
Study II was approved by the Danish Health Authorities j.nr. 3-3013-573/1. No ethical clearance 
was required for study upon request to the regional scientific ethical committee for Southern Denmark 
(confirmed by email 18.03.2014) for study II.  
Study III was approved by the ethical committee (S-20140055) and was executed in accordance 
with the Declaration of Helsinki. Study III registered in ClinicalTrials.gov with the number 
NCT02422316. 
The Danish Data Protection Agency registered study II with 2008-58-0035 nr 1086 and study III 
with 2008-58-0035 nr 1092. Written informed consents to access patient records and for 
participation for CT scan were obtained from the participants.   
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Summary of results: Study II and III 
Study II 
The study sample consisted of 1027 patients. Complete follow-up time was one year; two 
patients left Denmark before the end of follow-up time and were accounted for until emigration.  
The median age of the study population was 54 years (IQR: 47-62 years). The majority of 
patients consisted of women (55%).  
During one year follow up the composite endpoint was 2.5% (95% CI 1.6%-3.5%). 0.7% (95% CI: 
0.2%-1.2%) died. Compared to the general population the standardised mortality ratio was 1.2 
(95% CI: 0.5-2.4). 0.2% (95% CI: 0-0.5%) had an MI. 1.7% (95% CI 0.9%-2.4%) were 
revascularised – acutely and non-acutely, UAP was found in 0.4% (95% CI: 0.01%-0.1%).   
Cardiac-related endpoints (without all-cause mortality) isolated composed 1.9%. The majority 
of the endpoints occurred in males (73%). Male gender was a significant risk factor for a cardiac-
related clinical endpoint with HR=4.7 (95% CI: 1.6-14.0) and for the composite endpoint that 
also included all-cause mortality. Table 3 shows the clinical endpoints for NSCP patients. 
Other characteristics that identified patients with a cardiac-related endpoint were Charlson 
score >=1, previous CAD, hypertension, hypercholesterolemia, diabetes and use of statins 
(cholesterol lowering medication). HR was less significant when all-cause mortality was 
included.   
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Table 3 
Hazard ratio for exposure variables and endpoints during 1 year of follow up 
Clinical features and prognosis in patients with non-specific chest pain after the introduction of highly sensitive 
troponins. Paper II, Table 3.  
Characteristics Al l  cl inica l  events Cardiac cl inica l  events Al l -cause morta l i ty
(n=26) (n=19) (n=7)
Female 1 1 1
Male 3.4(1.4-8.1) 4.7(1.6-14.0) 1.7(0.4-7.6)
Age/years
40+ 1 1 omitted
50+ 1.1(0.3-4.0) 1.0(0.3-3.5) 1
60+ 2.8(0.9-8.4) 1.8(0.6-5.6) 5.6(0.7-46.7)
BMI<25 kg/m2 1 1 1
BMI>25 kg/m2 3.0(1.0-7.6) 4.6(1.1-19.7) 1.4(0.3-7.0)
Charlsons  score=0 1 1
Charlsons  score>=1 3.2(1.5-6.9) 1.9(0.7-4.8) 19.5(2.4-162.3)
Smoking
0-12 package years 1 1 1
>12 package years 1.9(0.8-4.3) 2.1(0.8-5.3) 1.6(0.4-7.2)
Alkohol  0-2 U /week 1 1
Alkohol  >2 U/week 0.8(0.4-1.7) 0.9(0.3-2.1) 0.7(0.2-3.1)
Comorbidi ty
Not known coronary artery disease 1 1 1
Coronary artery disease 3.3(1.5-7.3) 3.8(1.5-9.5) 2.1(0.4-11.0)
Not known ischemic cerebra l  disease 1 1 1
Ischemic cerebra l  diease 1.7(0.4-7.0) 1.1(0.2-8.3) 3.4(0.4-27.8)
Not known with extremity i schemia 1 1 1
Ekstremity i schemia 7.4(2.2-24,5) 3.1(0.4-23) 23.5(4.6-121.0)
Not known supraventricular tachycardia 1 1 1
Supraventricular tachycardia 1.5(0.4-6.4) 1.0(0.2-7.6) 3.0(0.4-25.2)
None of the above mentioned comorbidi ty 1 1 1
Combined i schemic comorbidi ty* 4.0(1.9-8.7) 3.6(1.5-8.9) 5.5(1.2-24.4)
Not known hypertens ion 1 1 1
Known  hypertens ion 5.2(2.1-12.8) 5.8(1.9-17.5) 3.9(0.8-20.2)
Not known hypercholesterolemia 1 1 1
Known hypercholesterolemia 2.5(1.1-5.9) 6.0(1.7-20.6) 0.5(0.1-2.5)
Not known diabetes 1 1 1
Known diabetes 5.0(2.2-11.6) 5.2(2.0-13.7) 4.7(0.9-24.1)
No fami ly his tory of CVD 1 1 1
Fami ly his tory of CVD 1.7(0.7-3.8) 1.6(0.6-4.0) 2.3(0.4-11.8)
Triglycerides<1 mmol/L 1 1 1
Triglycerides>=1 mmol/L 1.4(0.5-3.8) 1.0(0.4-2.7) n.c
Tota l  cholesterol<5 mmol/L 1 1 1
Tota l  cholesterol>5 mmol/L 0.5(.2-1.2) 0.4(0.2-1.1) 1.1(0.2-5.2)
LDL<3 mmol/L 1 1 1
LDL>3 mmol/L 0.5(0.2-1.1) 0.3(0.1-1.0) 1.1(0.2-5.4)
HDL>=1 mmol/L 1 1 1
HDL<1 mmol/L 2.1(0.8-5.5) 3.0(1.1-8.5) n.c
No s tatins 1 1 1
Statins 2.8(1.3-6.2) 4.3(1.8-10.6) 0.7 (0.1-5.5)
*Combined ischemic comorbidity consists of coronary artery disease, ischemic cerebral disease and ekstremity ischemia.
n.c: not calculated, CVD: cardiovascular disease, LDL: Low density lipoprotein,  HDL: High density lipoprotein
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Study III 
The study population consisted of 229 patients.  The DanRisk population represented the 
general population and contributed with 722 patients for comparison.   
Our population consisted of 30-70 years old, while DanRisk was 50 and 60 years old. The mean 
age of our population was 52 years and 55 years in DanRisk, respectively.   Significantly more 
patients were known with hypercholesterolemia and had a family history of cardiovascular 
disease in the study population, while significantly more people were smoking in the DanRisk 
population.  
The prevalence of CAC was 54% in NSCP population and 52% in DanRisk, respectively. No 
significant difference was found in the prevalence of CAC (CAC>0 AU) between NSCP and 
DanRisk patients. The odds ratio for presence of CAC was 1.3 (95% CI: 0.9-1.9) for NSCP 
compared to DanRisk. In the NSCP group 0.9% (95% CI: 0.2%-2.9%) were re-vascularised 
during one year follow up. Cardiac death, future MI, unstable AP or ventricular tachycardia did 
not occur in the study population. In DanRisk clinical endpoints occurred in 4/ 772, 0.6% (95% 
CI: 0.2%-1.3%). One cardiac-related death, two with MI, and one with ventricular tachycardia.  
No significant difference between the study population and the DanRisk population was 
demonstrated in the association of CAC with clinical endpoints.  
A group of NSCP patients from the main study (Study II) were referred for further cardiac 
imaging at index admission (n=211). The group referred at index admission had an event rate of 
5.2% (2.8%-8.9%) vs. 0.9% (0.1%-2.9%) in our study sample during one year follow up.  A 
significant difference between the outcome in patients referred directly for further 
investigations and DanRisk patients, 0.6% (95% CI: 0.2%-1.3%) could be shown.  Table 4.   
   Referred for cardiac testing    Study population  DanRisk population   
        
Number(n)  211  229  722  
Event (n)  11  2  4  
% (95% CI)  5.2 (2.8-8.9)  0.9 (0.1-2.9)  0.6 (0.2-1.3)  
                
 
Table 4 
Clinical event rate for patients referred for cardiac investigation at index , NSCP, and the DanRisk population. 
Non-contrast cardiac CT scan as a risk stratification tool in non-specific chest pain patients. Paper III, table 5. 
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Discussion
 
Summary of key findings  In these cohort studies that addressed patients with chest pain and with an acute visit to the 
emergency department and cardiology department, we found the following; 
i. Fewer patients are diagnosed with NSCP and more patients with MI after the hsTn 
implementation 
ii. The risk of future MI within one year is five times lower in NSCP patients compared to MI 
patients after the hsTn implementation.  
iii. No significance in mortality was shown in NSCP patients before and after the hsTn 
implementation. 
iv. The all-cause mortality for NSCP patients after hsTn was 1.9% (study I) and  
0. 7% (Study II) and comparable with the standardised mortality rate adjusted for 
gender and age in the general population. 
v. The one-year cardiac-related events were 1.9% and occurred primarily in males. 
i.  Risk factors associated with clinical endpoints were male gender, Charlson score >=1, 
previous CAD, hypertension, hypercholesterolemia, diabetes and use of statins. 
ii. The prevalence of coronary artery calcification in NSCP patients did not differ from the 
DanRisk population.  
iii. The rate of cardiac-related events in NSCP patients did not differ from the DanRisk 
population.  
iv. No significant difference in the rate of clinical endpoints was shown for patients with 
CAC=0 AU and CAC>=0 AU.   
i.  Patients who were referred for cardiac imaging testing at index visit had a less 
favourable prognosis than the DanRisk population.  
 
The major clinical endpoints are further listed in Table 5.  
 
 
 
Table 5 
The endpoints for the NSCP population in the three studies 
 
 Study I 
(Cohort 1 and 2) 
Study II Study III 
Age (years) 
 
Median 65 and 62 Median 54 Mean 52 
Mortality 
 
3.1% and 1.9% 0.7% - 
Cardiac-related endpoints 0.9%  and 0.4% 1.9% 0.9% 
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Comparison with existing literature 
Chest pain groups 
In all three studies, we chose to identify chest pain patients by discharge diagnosis and troponin 
measurements. In addition, in study II and III we excluded everyone with a coronary 
angiography performed during index visit as they, at one point, must have been suspected for 
CAD. In the mentioned criteria there is an implicit selection criterion, as it is a clinician 
dependent assessment, which patients are chosen to be sent home without a troponin 
measurement. These criteria also imply that patients with atypical chest pain and without 
troponin measurement are at risk of not being represented in this study as one out of three 
patients with MI do not present with chest pain (29). 
In study I, we showed that about half of the chest pain population consisted of NSCP patients. 
This is consistent with a previous study (22). The decline in NSCP patients (study I) after hsTn is 
consistent with more patients were diagnosed with MI and other heart-related conditions as 
even minor myocardial necrosis is diagnosed (59). Our results are in concordance with other 
studies that show an increase in MI diagnoses (59, 73). We did not include unstable AP patients 
in study I. There were very few patients with this discharge diagnosis. However, these findings 
support that unstable AP is a diminishing diagnosis (73), as previous unstable AP patients are 
now diagnosed with MI. This implies that the future approach for distinguishing between acute 
and non-acute chest pain diagnoses composes two groups:  stable AP that is non-acute and MI 
(74).    
Characteristics and risk factors for NSCP patients 
In study I, we showed that NSCP patients were younger and included a higher proportion of 
females compared to MI, stable AP, and other heart-related conditions patients. Even further the 
comorbidity (Charlson index >=1, use of beta-blockers/antidiabetic and cholesterol-lowering 
medication) was lowest in NSCP patients. In Study II we also found that women comprise the 
majority of NSCP patients. The median age for study II was 54 years (IQR: 47-62 years). 
Considering the lower age limitation in study II it is comparable with study I age with a median 
of 56 years (IQR: 45-67 years). Our results correlate with Durand et al. (22) who, before hsTn 
implementation found a lower mean age, more women and fewer with a known risk factor in 
NSCP patients compared to patients with acute MI.   
In our study male gender was significant and associated with a worse endpoint. The measured 
cholesterol levels showed no significant association with the outcome. In contrary, increased 
LDL values and total cholesterol values seemed to have a protecting effect on future CAD. A 
confounder here could be that patients were already treated with statins which means that 
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laboratory values were decreased for cholesterol and thus we did not find an association 
between increased cholesterol and future CAD.  
Several risk score tools have been developed for the purpose of risk stratification of chest pain 
patients and especially the HEART score has been proposed as a tool for predicting MI, the need 
for revascularisation and death among chest pain patients in the Emergency Department (75). 
The HEART score is based on history, ECG,  age, risk factors and troponin results (35).  The 
Systematic COronary Risk Evaluation (SCORE) algorithm, that also considers country of origin 
and gender in its risk stratification, was developed for the estimation of 10-year cardiovascular 
risk. However, it is intended as a tool for primary prevention of cardiovascular disease (34) and 
not for acute assessment. Omstedt et al. (37) investigating HEART score in NSCP patients 
showed that age, previous MI, hypertension, stroke, hyperlipidemia, diabetes mellitus and male 
gender are important risk factors among  NSCP patients. We found the same risk factors to be of 
significance in our study. The modified Goldman risk score, on the other hand, is mainly based 
on chest pain characteristics (76, 77). These characteristics were not found to be of significance 
in our cohort. The established risk scores, however, differ in performance depending on the 
hsTn assays; hence the use for rapid rule out is for the present limited (76).  
 
Non-contract cardiac CT and NSCP patients 
Our study is the first study to evaluate non-contrast cardiac CT in acute patients with NSCP. No 
difference in CAC prevalence and CAC associated prognosis was demonstrated between NSCP 
patients and the general population represented by the DanRisk population (49) in this study. 
The role of CAC in asymptomatic individuals is established and shows an increased risk of CAD 
with increased CAC (45, 49, 50, 78). We found no association between CAC and CAD prognosis 
for NSCP patients. These findings and results from previous studies imply that similar 
indications as for the asymptomatic population could be applicable for NSCP patients.  
It has been shown that a single hsTn in combination with clinical judgment and admission ECG 
has a sensitivity of 100% for ruling out ACS (79). This corroborates with our study where 
patients referred for cardiac investigation at index visit had significantly higher clinical 
endpoints than the general population in study III. Hence, neither clinical risk stratification nor 
cardiac CT can stand alone, the clinical judgment is important for this patient group.  
Prognosis for NSCP patients 
Study I and II investigated the one-year prognosis in NSCP patients and found 1.9% (95% CI: 
1.2%-2.5%) and 0.7% (95% CI: 0.2%-1.2%) all-cause mortality after hsTn, respectively. The 
95% CI showed no significant difference.  The studies differed in study design, population-based 
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design and clinical design, respectively. The age criterion also differs with study I including all 
patients above 18, while study II has an age limitation set at 30-70 years old. The only recent 
study (62) that addresses the 30-day prognosis of NSCP patients found similar results with an 
all-cause mortality of 0.2%-1.1% in patients directly discharged from emergency department 
and patients admitted briefly in emergency departments before discharge, respectively. Nejatian 
et al similar to study I found no significant difference in mortality rate for NSCP before and after 
hsTn. However, the risk factors for cardiovascular disease differed for the two time periods in 
their study. We tried to avoid this by exclusion of patients with similar visits to emergency 
departments and cardiology departments six months prior to index visit. 
Previous studies (61, 80, 81) that investigatedpatients excluded for acute MI have shown a 
mortality rate of 1.9 %-11 % before hsTn. The patient group of interests in these studies were 
patients excluded for acute MI and consisted of a more heterogeneous group (other diagnoses 
for chest pain) than our patient group that focused on patients without a diagnosis. 
Cardiac-related endpoints differed for the three studies, but the definitions were not alike. In 
study I, we did not include revascularisations as a cardiac endpoint. Study III consisted of a 
selected cohort in which all patients with previous known CAD were excluded. This could 
explain the differences found in the endpoints. Our results are consistent with Nejatian et al. 
(62) when consideration is given to weight the endpoints according to the cohort sizes (directly 
discharged vs. briefly admitted) that differ.  
NSCP patients compared to stable AP patients show a similar prognosis in mortality (82-84). 
The explanation might be improvement in prevention and treatment of stable AP patients (85, 
86)  and one contributory factor could be that the hsTn allocate lower risk patients with even 
small troponin increase to the MI group which leave patients with a lower risk profile in the 
stable AP group. This was probably also the plausible explanation for the lower mortality rate 
found in MI patients after hsTn, as more low-risk patients are diagnosed with MI after hsTn (59).   
Comparison of NSCP patients with the general population showed that the mortality did not 
differ, neither in study I or study II when adjusted for age and gender distribution after hsTn. 
This corroborates with Fagring et al. that demonstrated that the mortality in NSCP before hsTn 
was similar to the general population(61).  
Methodological considerations 
Selection bias 
Written informed consent had to be returned by postal mail or email for participation in study II 
and III.  However, less than 50 % returned the written informed consent primarily. A second 
contact and reminder were necessary for us to be able to obtain 85% acceptance. We do not 
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know the reason for why the remaining did not return the informed consent and thereby 
participation. It could be related to health issues, pure forgetfulness, or lack of involvement. It 
could also be logistic reasons as wrong addresses or wrong delivery from postal service. 
Nonetheless, it means that the included patients could represent a selected population. Previous 
studies have showed that patients who participate in clinical studies are healthier than those 
who do not and this could have underestimated the clinical endpoints in study II and III (87). 
However, we tried to account for comorbidity by a comparative analysis with the general 
population adjusted for age and gender. Furthermore, our population-based study (study I) 
shows similar results as the clinical study (study II) regarding prognosis. Even though study I 
was not dependent on consent it was based on discharge diagnosis which is dependent on the 
responsible clinician.  
In study III only four hospitals had a cardiac CT scanner Distance to the hospital could have 
influenced and demotivated the non-participants in this study and hence caused the lack of 
recruitment.  
Information bias 
Misclassification of exposure 
Study II was based on telephone interview with a structured questionnaire. Hence, majority of 
the data in this study were self-reported.  Patients might have -either unintentionally or 
intentionally- underestimated their cigarette or alcohol consumption due to social 
stigmatisation (88).  Furthermore, patients with an excessive use could have been less prone to 
participate in this study.   
The family history of cardiovascular disease was defined without age limitation in study II and 
III.  In study III, The DanRisk (49) definition of family history was known cardiovascular disease 
for a first degree relative male < 55 years and female < 65 years. In our study, we did not include 
the age limitation which could mean that this risk factor is overestimated in our study cohort. 
We tried to minimize recall bias by conducting the interview within three days of discharge.   
Misclassification of clinical endpoints 
MI ICD-10 discharge diagnoses have previously been validated with medical records and had a 
positive predictive value of 93% (65, 89). Mortality data were complete (90). The validity of 
NSCP diagnoses is unknown.  
The hospitals get financial reimbursement from the government as health care is free in 
Denmark.  The amount of reimbursement is determined by the diagnosis. This can cause some 
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diagnoses to be preferable compared to others and can lead to a misclassified incidence and 
prevalence of the diagnosis of interest.  
  
Limitations 
All three studies focus on patients with chest pain and a troponin measurement and find 
patients diagnosed with NSCP  to be of low risk. However, the group of patients with chest pain 
and who by the attending physician is assessed to be at low risk of cardiac event and thus do not 
have a troponin measurement were not accounted for in this thesis. Hence, we do not know their 
prognosis and the extent of missed diagnosis, which is also highly important knowledge and 
therefore limits the generalisability. A previous study that used a less sensitive assay showed 
that less than 1% of patients discharged without acute coronary syndrome diagnosis have an 
adverse outcome within 30 days (91).  
In study I, one of the main limitations was that we did not have the time to validate the final 
diagnoses used for stratification of the groups. We also chose not to include unstable AP in study 
I. This group consisted of very few patients which corroborate with other findings that unstable 
AP is a decreasing and small group (73). 
In Study II and III, few endpoints occurred during follow up. A larger study population could 
have been more confirmative of the results, but the findings we believe would be the same. 
However, a larger study could have allowed us to conduct a prognostic aspect for risk 
stratification of NSCP patients in study II. Due to the few events, it was not possible to perform a 
multivariate analysis.   
Both study II and III had upper limits of 70 years old. This is probably why we find a difference 
in the one-year mortality between study I and II.  By exclusion of patients over 70 years, we 
excluded a higher risk group of CAD. However, our rationale for this was that it is well known 
that coronary calcification and thereby CAC was higher with increased age and that CAC was 
thus not useful in the elderly (35, 75).  However, the mortality rates in study I and II, 
respectively 1.9% and 0.7%, were comparable with the general population adjusted for age and 
gender and thereby demonstrate that NSCP patients do not have an increased mortality rate 
compared to the general population.  
In Study II revascularisations composed the majority of the endpoints. Some of these 
revascularisations could have been derived from the index visit and could thereby reflect a 
higher event rate than the actual.  
Non-participants 
In study II and III, we recruited fewer patients than expected. In study II we were able to recruit 
1027 patients who fulfilled the criteria for inclusion. Approximately 50% of all patients with a 
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normal troponin were eligible for participation. In Study III we included 229 out of 441 patients 
who were assessed to be eligible. As study III recruited from study II, more patients could have 
been eligible if more patients had been recruited for study II. We could possibly have recruited 
more patients by study inclusion before discharge in the departments by direct approach. 
However, due to resources, we were not able to have covered all departments and all visits (day 
and night). A previous study has demonstrated that patients who did not participate in clinical trials were at 
risk for worse outcome (87).  This could imply we are underestimating the adverse prognosis for 
NSCP patients. For study II and III detailed information of those who were not included could 
not be reported. We were not able to report on the patients who we could not contact, and for 
those who declined participation by not returning their informed consent, we were not allowed 
to use their information from the telephone interview.  
For a complete information and data for NSCP patients, register-based studies would be more 
appropriate, as they are not dependent on patient inclusion and consent. However, we would 
not have been able to gather the same detailed information (family history of cardiovascular 
disease, smoking status, and detailed medical history) from register-based studies. Neither 
would we be able to control the validity of the discharge diagnoses for NSCP.  
 
Generalisability  
All three studies involved the patients in the southern part of Denmark from several hospitals. 
We tried to consider the demographic differences by this approach. The number of participants 
in study II and III compared to eligible patients, and lack of information besides age and gender 
limits the external validity. However, the combination of the clinical studies and population-
based study confirming the same results adds validity to our results. 
We believe the results are applicable to countries where the health care system is comparable to 
the Danish health care system. The number of acute chest pain patients is around 6000 patients 
yearly in the Region of Southern Denmark. We included hospitals that serve as an invasive 
centre for the acute treatment of acute MI and hospitals, from where patients had to be 
transferred to the invasive centre, representing a broad patient population.  
Certain eastern European countries have shown higher mortality rates regarding CAD compared 
to the rest of Europe (1, 2). Based on this, the generalisability of our studies would apply to 
Western Europa and especially the Nordic countries.  
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Clinical implications   
All three studies showed that the prognosis for NSCP patients was good regarding mortality and 
clinical cardiac-related events during one year follow up. The few clinical endpoints showed that 
the risk assessment taking place during the hospital visits identify those at risk for future CAD.  
Our studies showed that even with hsTn, clinical assessment is important and allows us to 
identify patients with a higher event rate (study III). Physician-based assessment is also 
important in the discrimination between unstable AP and NSCP patients in the emergency 
departments and cardiology departments. The diagnosis given is of high importance for the 
further investigation and visitation.  
These studies make us able to reassure NSCP patients of their good prognosis compared to other 
chest pain patients. We know from other findings that NSCP patients have more frequent contact 
with the health care system (60). Being able to reassure the patient might have an implication 
for the re-admission rate for this patient group.  
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Conclusion
 
Based on the findings in the three papers the following conclusions were made:  
The implications of hsTn implementation were that fewer patients were diagnosed with NSCP as 
even minor hsTn increases were identified and stratified into other diagnosis groups as MI and 
other heart-related conditions.  The risk of future MI was 1/5 in NSCP patients compared to MI 
patients. The mortality for NSCP patients was not significantly different from the MI group. The 
mortality after the hsTn implementation compared to before the hsTn for NSCP patients did not 
differ. The causal explanation is that more low-risk patients were now allocated into other 
diagnoses groups due to hsTn, and there for the prognosis for these groups were more beneficial 
than previously. 
The NSCP patients had, during a year of follow-up period, a favourable prognosis for all-cause 
mortality that was comparable with the general population. Very few cardiac related endpoints 
occurred during one year follow up. The majority of the events were revascularisations and their 
initial association with the index visit is undetermined. Only 0.2% had a MI during one year.  
The identified risk factors were male gender, Charlson score >=1, previous CAD, hypertension, 
hypercholesterolemia, diabetes and use of statins. Especially male gender was associated with a 
higher risk of clinical endpoints.   
The number of clinical events during one-year follow-up was also low in study III for the NSCP 
patients and the DanRisk population. Significantly more events occurred in the group of patients 
who were referred directly for further investigations from the index visit. No significance was 
found between the number of events occurring in patients with CAC=0 and CAC>=0.   
Perspectives 
Even though, the implementation of hsTn has led to a better prognosis among all patients groups 
regarding all-cause mortality and cardiac-related death, the clinical evaluation of the patients is 
still crucial - especially, in the discrimination between unstable AP and NSCP. More patients are 
admitted with MI due to hsTn which means more patients are acutely admitted and acutely 
examined; this puts a larger workload on our departments receiving these patients and requires 
additional resources to meet the demands.    
Risk stratification among NSCP patients is, on one hand, important due to the seriousness of a 
cardiac-related event. On the other hand, the numbers of events are very few and the balance 
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between the resources used on this low-risk patient group and their future risk of adverse event 
has to be taken into consideration. Especially regarding cardiac-CT, we showed that this was not 
further indicated in NSCP patients compared to the general population. Nonetheless, the role of 
non-contrast cardiac CT for asymptomatic individuals with a higher CAC is of relevance and we 
did not demonstrate that the indication was smaller in NSCP patients than in asymptomatic 
individuals.  
The main endpoints found in this study were revascularisations - acute and non-acute. This 
implies that an important part of the clinical assessment of NSCP patients was to evaluate 
whether the patient should be seen in an outpatient clinic for further non-acute cardiac 
investigations based on the risk factors discussed above.   
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Epilogue 
 
After completing these three studies my answers for the initially asked questions are: 
To my patient, I would tell them not to be concerned. Their risk of future MI is much lower than 
for patients with an index MI. And their future risk of coronary disease or death is not higher 
than for anyone else of same gender and age.  
To my fellow colleague, I would say; “No worries. You can send this patient home with a good 
consciousness. This patient’s risk of future CAD is comparable to the general population. The 
new hsTn do not catch everything, but close to. Your clinical judgment is reliable and essential in 
this setting. The CT scan does not seem more useful for these patients than anyone else because 
you are able to identify patients, who need it by your own clinical assessment.”     
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Abstract 
Aim: Among patients with acute chest pain we wanted to determine the frequency and prognosis of non-specific 
chest pain (NSCP) compared to different chest pain diagnoses before and after implementation of highly 
sensitive troponins (hsTn). 
Methods: A population-based study involving chest pain patients from departments of Emergency Medicine and 
Cardiology in the Region of Southern Denmark before and after implementation of hsTn. All patients above 18 
years with an acute chest pain visit, troponin measurement and with discharge diagnoses of MI, stable angina 
pectoris (AP), other heart-related conditions or NSCP. Primary endpoints were all-cause mortality, MI, cardiac 
arrest and ventricular fibrillation. 
Results: 5 353 patients (2152 before and 3200 after implementation of hsTn).  There was a 8 % (CI 5.9%-10.6%) 
relative decrease in patients who were diagnosed with NSCP after implementation of hsTn, and a 42.6% (28.3%-
57.8%) relative decrease in stable AP patients, while the number of patients with MI and other heart-related 
conditions increased with 20.9% (CI: 14.4%-28.6%) and 13.9% (CI 9.8%-18.7%), respectively. The risk of 
future MI was decreased by a factor 5 in NSCP patients compared to patients with a discharge diagnosis of MI. 
The mortality for NSCP patients declined non-significantly from 3.1 % (CI: 2.2%-4.1%) to 1.9 % (CI:1.2%-
2.5%) after implementation of hsTn. The standardised mortality rate for NSCP patients was comparable to the 
general population: 1.2 (CI: 0.8-1.7). The mortality rate was significantly decreased for MI group from 18.7% 
(95%CI: 14.3%-23.2%) before hsTn to 11.3% (95% CI: 8.7%-14.0%) after hsTn.  
Conclusion: The prognosis for patients with non-specific chest pain is good and the mortality is low and 
comparable to the general population. 
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Introduction
 
Chest pain evaluation in the emergency departments and cardiology departments consists of clinical 
judgment, ECG assessment and troponin measurements (1). While nearly one out of five patients with 
chest pain have an acute myocardial infarction (MI) (2), a group of patients with acute chest pain, 
normal ECG and troponin does not get a discharge diagnosis explaining the cause of their chest pain 
and these patients are categorised as non-specific chest pain (NSCP). Previous studies before the 
implementation of highly sensitive troponins (hsTn) in clinical practice showed that NSCP patients 
have more contacts to the health care system and a higher use of medication compared to the general 
population (3).  
In the era of hsTn, where even minor myocardial damages causes a rise in hsTn, recent studies have 
demonstrated that use of hsTn has changed the distribution of cardiac causes of chest pain, with a 
decrease in unstable angina pectoris (AP) and an increase in non -ST-elevation myocardial infarction 
diagnosis (4, 5). In this light, it may be expected that the prevalence and prognosis of NSCP patients 
also have changed – but this issue has only been scarcely described so far. A recent Swedish study (6) 
compared the time period prior to and after the routine use of hsTn and did not find any significant 
difference in the 30 days clinical endpoints for NSCP. Another study (7) demonstrated that 0.5% of 
NSCP patients were diagnosed with MI within 30 days from index contact for chest pain in the 
Emergency Department. A longer follows up time for NSCP patients is required to assess the need for 
further diagnostic efforts for this patient group as well as for the patient's information and concern for 
their future risk of cardiac-related events. 
The aim of this study was to investigate if there has been a change after the implementation of hsTn in 
the relative distribution for patients diagnosed with NSCP, MI, stable AP and other heart-related 
conditions, and to compare the cardiac-related events and all-cause mortality for NSCP patients with 
patients with MI, stable AP and other heart related conditions and the general population.  
 
Method 
 
Study population 
This study included all citizens in the Region of Southern Denmark  (1.201.955 inhabitants in 2013 ), 
aged 18 years or older with an acute contact to an Emergency Department or Cardiology Department 
during 2013 and who had at least one troponin measurement done within 24 hours of their admission 
together with a discharge diagnosis of MI (non-ST elevation MI or ST elevations MI), stable AP, other 
heart related conditions (like aortic dissection, pulmonary embolus, pericardial diseases, endocardial 
diseases, supraventricular arrhythmia) or NSCP (chest pain and no obvious reason) . The International 
classification of diseases diagnosis codes with 10th revision (ICD-10) are specified in appendix 1.  
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Study design  
The study was a population-based cohort study involving patients from all hospitals in the Region of 
Southern Denmark (Sonderborg, Aabenraa, Haderslev, Kolding, Vejle, Esbjerg, Odense and 
Svendborg). In Denmark, every inhabitant is entitled to free healthcare. Patients with a measurement 
of troponin in any of these hospitals from 1st January 2013 to 31st December 2013 were included in the 
study and followed to 30th June 2015 or until emigration or a clinical endpoint occurred, whichever 
came first. Patients were referred to the emergency department or cardiology department by their 
general practitioner, emergency services, or arrived directly to the hospital without any pre-hospital 
visitation. Patients highly suspected of coronary causes of chest pain were referred directly to the 
cardiology department while others were first seen in the emergency department. 
All patients with at least one troponin measurement were identified through the electronic central 
laboratory system in the region. The assays for troponin were changed during the course of this study. 
Departments using contemporary troponin I changed to hsTn I on the 11th May 2013 and departments 
using contemporary troponin T changed to hsTn T on the 26th of June 2013. The total cohort was split 
into a pre-hsTn cohort (cohort 1) and a post-hsTn cohort (cohort 2) according to these dates. 
All admissions were classified by International Classification of Disease codes using the 10th revision 
(Appendix 1). Based on troponin levels and discharge codes, four patient groups were defined: 
 
a) MI: Troponins elevation and discharge by a diagnosis of acute non-ST elevation MI or ST 
elevation MI. 
b) Stable AP: Normal troponins and the diagnosis stable angina pectoris. 
c) Other heart-related conditions: Normal or elevated troponin but diagnosed with serious 
cardiac disorders other than acute MI (Diagnoses are listed in Appendix 1).  
d) NSCP: Normal troponins and no serious cardiac disease and discharged with an unspecified 
diagnosis. 
 
Patients with a discharge diagnosis of other aetiology were not included. 
 
The first contact to an emergency department or cardiology department during 2013 for chest pain 
with the defined discharge diagnoses was defined as the index contact. Patients with a visit and any of 
the above discharge diagnosis six months prior to the index visit were excluded. This was due to 
different inclusion periods for the two cohorts, January to May (troponin I), January to June (troponin 
T) for cohort 1 and May to December (troponin I) and June to December (troponin T) for cohort 2, 
respectively.  By this exclusion, we avoided that cohort 1 could potentially have a more frequent 
admission rate with the same diagnosis prior to the index contact.  
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All Danish inhabitants have a unique civil personal registration number that can be used to identify a 
subject in all registers (8). Patients without a valid personal identification number were excluded in the 
study. The identification number was used to combine the level of troponin with the final discharge 
diagnosis. From the Danish civil registration system information on vital status, emigration, 
immigration, and place of residence were obtained (9). The Danish National Patient Registry register 
at individual level all hospital contacts, discharge diagnosis and hospital-based procedures (10). 
Odense University Pharmaco-epidemiological Database register information on an individual level on 
redeemed medications (11). Prescribed medications collected at any pharmacy up to three months 
before index admission was included. Medications including anti-diabetic medicine, beta blockers, and 
cholesterol-lowering medication were identified by ATC codes. The applied ATC codes are listed in 
Appendix 2. 
The Charlson comorbidity index was used to describe the patient’s comorbidity (12, 13). In this study, 
Charlson comorbidity index was based on the primary discharge diagnosis for all admissions 10 years 
back. 
 
Troponins 
Before the implementation of hsTn (cohort 1), troponin I was analyzed by use of Architect c16000 
(Abbott Diagnostics, Lake Forest, Ill). Upper reference limit was the 99th percentile of 28 ng/mL. The 
10% coefficient of variation was 32 ng/mL. The decision limit was at 30 ng/mL for MI. After the hsTn 
implementation (cohort 2) troponin I was analyzed by Abbot Diagnostics Architect with upper 
reference limit of the 99th percentile of 25 ng/L. The 10% coefficient of variation was at 5 ng/L. The 
decision limit for MI was set at >= 25 ng/L. 
Concerning troponin T, this was in cohort 1 analysed by Roche Diagnostic Elecsys 2010, modular 
analytics E170, Cobas e411, cobas e601. The 99th percentile cut off was 14 ng/L. The 10% coefficient 
variation was 13 ng/L. The decision limit was set > 50 ng/L for MI. In cohort 2 the hsTn T decision 
limit was changed from 50 to 14 ng/mL.  
 
Endpoints 
All-cause mortality was accounted for from index admission. Readmission with MI, ventricular 
fibrillation or cardiac arrest was from ≥ 8 days from the date of discharge after the index visit. 
Appendix 3. 
The following visits after the index visit accounted as a clinical endpoint. An endpoint was the first 
defined endpoint occurring during the follow-up period.  
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Statistical analysis 
Continuous variables are presented as medians and interquartile range (IQR). Significance was tested 
with rank sum test. Categorical variables are listed as frequencies and percentages and tested by Chi-
square test 
All events were pooled to a combined endpoint. Time to event was reported by accumulated plots. 
Cox regression was used to calculate the hazard ratios (HR) for the risk of an event. Results were 
reported unadjusted and adjusted for age, sex, Charlson score, use of beta-blocker, anti-diabetes and 
cholesterol-lowering medication.  
Mortality was compared with the mortality in the general population. From Statistics Denmark (14) 
we found the regional population number and deaths in 2013. Based on this we calculated the age (10 
year age band) and gender-adjusted standardised mortality rate for the general population and 
compared it with the observed death rate (including 95% confidence interval (CI)) for the NSCP 
group. 
This study was reported according to the STROBE guidelines for cohort studies (15). Analyses were 
performed with STATA 14.2 0 (StataCorp, College Station, Texas). 
 
Ethics 
The study was registered with The Danish Data Protection Agency (2008-58-0035 nr 1085) and 
approved by the Danish Health Authorities (j.nr. 3-3013-862/1). According to Danish law patient 
consent is not acquired for register-based studies.  
 
Results
 
16 135 patients had a troponin measurement in an Emergency Department or Cardiology Department. 
6 656 had a relevant diagnose and a troponin measurement was taken within 24 hours of the initial 
visit time. After the relevant exclusion the final cohort for analysis consisted of 5 352 patients (Figure 
1).  
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Figure 1: Patient inclusion 
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 Changes in the relative distribution of diagnosis after hsTn 
The patients were stratified into two cohorts. A cohort with index admission before implementation of 
hsTn including 2 152 patients (Cohort 1) and another after implementation of hsTn with 3 200 patients 
(cohort 2). Cohort 1 patients were slightly older and had a higher use of beta-blockers (Table 1). The 
frequencies of the four predefined patient groups changed after the introduction of hsTn. The change 
was significant for all groups; MI with a 20.9%(CI: 14.4%-28.6%) relative increase, other heart-
related conditions also increased with 13.9%(CI 9.8%-18.7%) while Stable AP had a 42.6%(28.3%-
57.8%) relative decrease and an 8 % (CI 5.9%-10.6%) decrease among NSCP.  
 
Table 1: Baseline characteristics of the cohorts including the frequency of the discharge diagnosis before and after hsTn implementation.
 
MI: myocardial infarction, SAP: stable angina pectoris, OHC: other heart-related conditions, NSCP: non-specific chest pain. 
 
In general for all groups in cohort 2  (after hsTn) compared to cohort 1 (before hsTn), the median age 
was lower, fewer patients with a Charlson >1, and fewer patients used medication (Table 2).  The 
NSCP groups were younger, had a larger proportion of women, less comorbidity and the smallest use 
of medication compared to MI, SAP and OHC patients in both cohorts. 
 
Characteristics n %(CI) n %(CI)
Total 2 152 3200
Male 1215 56.5(54.4-58.6) 1794 56.1(54.3-57.8)
Median age /years (IQR) 65(52-76) 62(50;74)
Charlsons index>= 1 723 33.6(31.6-35.6) 965 30.2(28.6-31.8)
Medications last 3 months
Anti-diabetic 207 9.6(8.4-10.9) 286 8.9(8.0-9.9)
Beta blocker 512 23.8(22.0-25.6) 617 19.3(17.9-20.7)
Cholesterol lowering medication 527 24.5(22.7-26.3) 736 23.0(21.5-24.5)
Discharge diagnosis
MI 299 13.9(12.4-15.4) 538 16.8(15.5-18.1)
SAP 100 4.7(3.8-5.5) 86 2.7(2.1-3.3)
OHC 544 25.3 (23.4-27.1) 922 28.8(27.2-30.4)
NSCP 1209 56.2(54.1-58.3) 1654 51.7(50.0-53.4)
Cohort 1 Cohort 2
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MI: myocardial infarction, SAP stable angina pectoris, OHC: other cardiac-related conditions, NSCP: non-specific chest pain. IQR: 
interquartile range.  
 
Cardiac-related events and all-cause mortality after hsTn implementation 
Table 3 lists the number of endpoints during the first year follow-up for all four diagnosis groups. The 
median follow up time was 688 days (IQR; 598:797 days), while the median time to an endpoint was 
78 days (IQR: 13:212 days). 
There was a trend towards fewer composite endpoints for NSCP patients after hsTn implementation 
with 3.7% (95% CI: 2.7%-4.8%) before and 2.2% (95% CI: 1.5%-2.9%) after hsTn respectively, 
however, this was not significant. The only significant change was seen in the MI group for the change 
in mortality which was 18.7% (95%CI: 14.3%-23.2%) before hsTn and 11.3% (95% CI: 8.7%-14.0%) 
after hsTn, respectively. 
 
 
 
 
Table 2: Baseline characteristics of MI,  SAP,OHC and NSCP patients
Characteristics MI SAP OHC NSCP MI SAP OHC NSCP
n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%)
Total (n=299) (n=100) (n=544) (n=1209) (n=538) (n=86) (n=922) (n=1654)
Male 199 (66.6) 60(60.0) 316(58.1) 640(52.9) 369(68.6) 46(53.5) 511(55.4) 868(52.5)
Median age/years (IQR) 70(59-81) 69(62-80) 72(61-80) 59(47-71) 67(57-78) 64(55-72) 70(59-79) 56(45-67)
Charlsons index>=1 115(38.5) 40(40.0) 194(35.7) 374(30.9) 170(31.6) 37(43) 321(34.8) 437(26.4)
Medication last 3 months
Anti-diabetic 32(10.7) 15(15) 62(11.4) 98(8.1) 67(12.5) 10(11.6) 87(9.4) 122(7.4)
Beta blocker 70(23.4) 37(37) 177(32.5) 227(18.9) 102(19.0) 20(23.3) 239(25.9) 256(15.5)
Cholesterol lowering medication 67(22.4) 37(37) 137(25.2) 286(23.7) 128(23.8) 35(40.7) 219(23.8) 354(21.4)
Cohort 2Cohort 1
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*Composite endpoints consist of MI, cardiac arrest, ventricular fibrillation and all-cause mortality 
MI: myocardial infarction, OHC: other heart-related conditions, SAP: stable angina pectoris, NSCP: non-specific chest pain 
 
The mortality for the NSCP patients in cohort 1 and 2 are illustrated in Figure 2. No significant 
difference is shown between the cohorts during total follow up time. The crude one-year mortality rate 
in the NSCP group before hsTn was 3.1 %(CI: 2.2%-4.1%) and after 1.9 % (CI:1.2%-2.5%), ie. no 
significant difference, but a trend towards lower mortality in the NSCP group after the implementation 
of the hsTn. 
NSCP patients’ mortality compared with the general population’s mortality after hsTn implementation 
showed that the standardised mortality ratio for the NSCP group adjusted for age and gender was 1.2 
(95% CI: 0.8-1.7).  
 
 
 
 
 
 
 
 
 
 
n %(CI) n %(CI) n %(CI) n %(CI) n %(CI)
Total (n) 2 152 100 299 100 100 100 544 100 1 209 100
Death 164 7.6(6.5-8.7) 56 18.7(14.3-23.2) 2 2.0(0-4.8) 68 12.5(9.7-15.3) 38 3.1(2.2-4.1)
7 0.3(0.1-0.6) 0 0-(0-1.0) 1 0.01(0-3.0) 2 0.4(0-0.9) 4 0.3(0.0-0.7)
21 1.0(0.6-1.4) 12 4.0(1.8-6.3) 1 1.0(0-3.0) 1 0.2(0-0.6) 7 0.6(0.2-1.0)
182 8.3(7.2-9.5) 61 20.4(15.8-25.0) 4 4.0(0.1-7.9) 71 12.9(10.1-15.7) 46 3.7(2.7-4.8)
n %(CI) n %(CI) n %(CI) n %(CI) n %(CI)
Total (n) 3 200 100 538 100 86 100 922 100 1654 100
Death 186 5.8(5.0-6.6) 61 11.3(8.7-14.0) 2 2.3(0-5.6) 92 10.0(8.0-12.0) 31 1.9(1.2-2.5)
9 0.3(0.1-0.5) 2 0.4(0-0.9) 0 0(0-3.5) 6 0.7(0.1-1.2) 1 0.1(0-0.2)
32 1.0(0.7-1.3) 17 3.2(1.7-4.6) 2 2.3(0-5.6) 7 0.8(0.2-1.3) 6 0.4(0.1-0.7)
214 6.6 (5.8-7.5) 75 13.9(11.0-16.9) 4 4.7(0.1-9.1) 99 10.5(8.5-12.5) 36 2.2(1.5-2.9)
Cardiac arrest/VF
Myocardial infarction
Composite endpoints*
Cardiac arrest/VF
Myocardial infarction
Composite endpoints*
Cohort 2
Total MI Stable AP OHC NSCP
Table 3: One year endpoints before and after hsTn
Cohort 1
Total MI Stable AP OHC NSCP
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Figure 2: Accumulated mortality for NSCP patients before and after hsTn 
 
Table 4 shows the HR for the endpoints in the different groups with and without adjustment for age, 
sex, Charlson score, use of Beta-blockers, diabetes, and cholesterol-lowering medication for cohort 2  
(after hsTn). The MI group was baseline with HR=1. Compared to MI, NSCP patients had an HR of 
0.3 for combined endpoints primarily due to a much-reduced risk of MI, whereas the risk of death did 
not significantly differ between the groups.  
 
 
                    MI: myocardial infarction, SAP: stable angina pectoris, OHC: other heart-related conditions,  NSCP: non-specific  
                    chest pain. HR: hazard ratio. Unad HRj: unadjusted hazard ratio. 
 
Table 4: Risk for death and future MI  unadjusted and adjusted for sex, age, charlson, anti-diabetic,
 betablockers and cholesterol lowering medications for cohort 2.
Groups Unadj HR HR Unadj HR HR Unadj HR HR
MI 1 1 1 1 1 1
SAP 0.3(0.1-0.9) 0.5(0.2-1.3) 0.2(0.1-0.9) 0.3(0.1-3) 0.7(0.2-2.9) 0.8(0.2-3.6)
OHC 0.7(0.5-1.0) 0.6(0.5-0.9) 0.9(0.6-1.2) 0.7(0.5-1.0) 0.2(0.1-0.5) 0.2(0.1-0.5)
NSCP 0.3(0.1-0.2) 0.3(0.2-0.4) 0.3(0.2-0.5) 0.7(0.4-1.1) 0.1(0.04-2.6) 0.2(0.1-0.4)
Composite endpoints Death Future MI
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Figure 3 shows the risk of a combined endpoint, death or future MI, during a median the follow up of 
688 days. The lowest risk of a combined endpoint was found in NSCP patients. Stable AP has a wide 
CI interval due to few patients and few endpoints in this group. 
  
Figure 3: Accumulated endpoints for the four diagnosis groups. 
 
 
 MI: Myocardial infarction. OHC: other heart-related conditions, SAP: stable angina pectoris, NSCP: non-specific chest pain 
 
Discussion 
 
In this population-based study, we compared chest pain patients before and after hsTn implementation 
and found that the prevalence had changed with less proportion diagnosed with NSCP and stable AP, 
and more patients were diagnosed with MI and other heart-related conditions. 
The NSCP patients in this study had very few cardiac endpoints and no significant difference was 
found after hsTn was introduced. NSCP patients experienced a five times smaller risk of future MI 
compared to patients with an index MI. The first year mortality for NSCP patients were respectively 
 
 
71
3.1% and 1.9% before and after implementation of hsTn, but no significant difference was found. Of 
significant importance, the mortality in NSCP group was comparable with the general population.  
 
Prognosis for NSCP patients 
This is the first study to report the prognosis of NSCP patients compared to other patients with acute 
chest pain. Out of 16 135 patients with a troponin measurement in an emergency department or 
cardiology department 2 863 were diagnosed with NSCP, comprising 18%.  
The findings in our study are supported by the works by Reichlin et al and Nejatian et al (5, 6). 
Reichlin et al. showed that in patients without MI the cumulative 30-month mortality was 4.8%. The 
troponin assay used by Reichlin’s study was a hsTn assay. The average annual mortality rate in this 
study would approximately be 1.9% which is very consistent with our results (5). Similar to our study 
Nejatian found no difference in the 30 days mortality for NSCP patients before and after hsTn 
implementation, respectively.   
Other studies to be mentioned are Fagring et al(16), Ravn-Fischer et al (17) and Kelly et al (18). These 
studies are older (16) and included patients excluded for acute MI, however not specifically NSCP 
patients (17, 18). Patients excluded for acute MI could have other serious disorder for their chest pain 
explaining a different prognosis.  The first two mentioned (16, 17) showed a higher mortality rate of 3-
11% depending on age and gender. Fagring et al.’s study (16) reported from chest pain patients from 
2002-2006 and before the use of hsTn. The mortality rate for NSCP patients was higher in Fagring et 
al’s study, however, the mortality rate was not significantly different from the age-matched general 
population. A contributory reason for the decreased mortality in our study compared to Fagring’s 
could be the overall improvements in prevention and treatment strategies between Fagrings study 
(2006) and ours (2013). Ravn-Fischer et al from 2011 found the average one-year mortality was 3.2-
9.4% among patients without acute MI. Patients were included in 2008 before hsTn in this study. 
Kelly et al showed a lower mortality rate of 3% in non-MI patients during a median follow up time of 
48 months(18) using an assay that was one generation older than ours. Kelly’s study has a longer 
follow up time and consisted of patients without known CAD and therefore a lower risk patient group 
than ours. 
 
Comparison of other chest pain diagnoses 
The crude one year mortality for NSCP patients was not significantly different from stable AP, 1.9% 
(CI:1.2%-2.5%) and 2.3% (95% CI: 0%-5.6%) respectively. In patients with stable AP, Madsen et al 
(19) and Douglas et al (20) found an average annual mortality of less than 1%. Opposed to our study, 
both studies included outpatients with suspected AP. Furthermore, Madsen et al excluded patients with 
a  previous CAD. Thus, these studies included a lower risk population compared to our acutely 
admitted AP patients.  
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A recent study by D’Souza et al. (4) showed that the one-year mortality in non-ST elevations MI 
patients was 27% vs 14% in ST elevations MI patients. The one-year mortality for unstable AP, ST 
elevation MI and Non-ST elevation patients in total was 22%. Our MI group had a one-year mortality 
of respectively 18.7% (14.3%-23.2%) before implementation of hsTn and 11% (8.7%-14.0%) after. 
D'Souza et al used the Architect C16000 troponin assay which is an assay that is a generation older 
than our hsTn. An explanation for the improved mortality in our MI group after hsTn could be the 
better treatment and secondary prevention of CAD patients. The decreased mortality in MI patients is 
in concordance with the increasing prevalence of CAD patients in Denmark (21). However, we know 
from previous studies that patients, who were not diagnosed with MI, are now diagnosed with MI due 
to a lower threshold for MI diagnosis with hsTn (5). This could implicate that healthier patients with a 
better risk profile are stratified into MI groups, which can explain the better prognosis of MI patients 
found in our study. Patients with other heart-related conditions had the highest risk of death that could 
be caused by some of the high-risk conditions in this group like aortic dissection and pulmonic 
embolus. 
 
Limitations and strengths  
The national registries in Denmark, used for data gathering, are validated and documented (9-11). The 
diagnosis codes used for identifications of the patients were the final discharges diagnose code for the 
entire visit. These are clinician dependent and individual variation might be present and could be a 
limitation. We did not include secondary diagnoses that might have given us more information, as 
secondary diagnoses may reflect previous comorbidities instead of the cause of index visits leading to 
an overestimation of the diagnoses. This study accounted for total mortality from index visit and 
thereby reflecting the real morbidity associated with the diagnoses. To avoid overestimation of the risk 
of a cardiac-related event in cohort 1 (before hsTn) compared to cohort 2 (after hsTn), we excluded 
everyone with a previous admission with chest pain up to 6 months before the index visit.   
Selection bias can be present. There may be patients with chest pain that do not have a hsTn 
measurement, i.e. if it is assessed that the chest pain is not related to ischemic heart disease, and 
accordingly these patients cannot be accounted for. However, this should not affect the results before 
and after hsTn.    
Furthermore, it was difficult to differentiate between index admission related procedures and new 
acute procedures as some procedures can be conducted both acutely or subacutely after index 
discharge (i.e admitted at a secondary hospital and referred to a tertiary hospital for coronary 
angiography). We chose not to include revascularisation as an endpoint for the same reason. It can also 
be difficult to differentiate between a re-admission and a continuous admission if several visits are 
registered with only one day apart.  
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In this study, we did not include patients with unstable AP, as the number of these was very few and 
composed an even smaller group than stable AP patients. We decided that the statistical conclusions 
based upon this would be too inaccurate.  
 
Clinical implications 
Our study has important clinical implications. With the very sensitive hsTn, more patients will be 
identified with MI and treated accordingly. Even though the absolute number was not that high, the 
relative increase in MI patients was 21%, which means 21% more patients have acute investigations 
and treatment. Patients that previously would have been diagnosed as stable AP and NSCP and 
referred for non-acute out-patient investigations may now have a prolonged hospitalization until an 
invasive coronary angiography has been conducted. Accordingly, the prognosis and outcome for MI 
are expected to improve, as more patients with less extensive MI are diagnosed. However it also 
demands more resources from  emergency departments and  cardiology departments allocated to acute 
treatment, follow-up, and controls  
In clinical practice, the NSCP patients presently have a frequent contact with the health care system 
and a higher use of medication compared to the general population(3), but with the knowledge from 
our results we might be able to change this. The good cardiac related prognosis for NSCP patients 
makes physicians in an emergency department or a cardiology department able to reassure, and this 
might decrease the subsequent admission of these patients. This is significant since this group 
composes more than half of the chest pain population (Table 1).  
 
Conclusion
 
After implementation of hsTn an increasing number of patients with increased risk are identified. The 
mortality rate in patients with NSCP was low and comparable with the general population. The risk of 
future MI among NSCP patient was five times lower than among patients with new diagnosed MI. 
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Appendix 1  ICD-10 diagnoses for the four groups
 
 
 
 
 
 
 
 
 
Chest pain groups Diagnosis ICD codes
MI STEMI DI210B DI211B DI213B DI210A DI213 DI211A DI447 DI446
NSTEMI DI219 DI210 DI210A DDI211 DI211A DI214 DI248 DI249 DI256
Stable AP AP DI201 DI208 DI208D DI209 DI251 DI251B DI208E DI208E1
NSCP NSCP DR073 DR074 DZ035 DR072 DZ034
Other hear related Pulmonal embolus DI260 DI260A DI269 DI269A
 conditions
Cor pulmonale Di279
Pericardial diseases DI318 DI319 DI319A DI313 DI300 DI301A-E DI301 DI308 DI309 DI311
Endocarditis DI330 DI339 DI389
Myocardial disease DI409 DI429 DI428 DI428B DI428A DI420 DI421 DI422 DI426
Mitral valve diseases DI340 DI341
Aortic valve diseases DI350 DI351 DI352 DI358 DI358A DI359 DI442 DI442A DI443 DI443A
Supraventricular Arrythmia DI456C DI471 DI441A-E DI441 DI498 DI499 DI499A DI440 DI480 DI484
DI483 DI482 DI489 DI489A DI489B DI489C DI489D DI481 DI495 DI495B
Block DI446 DI447 DI451 DI451A DI452 DI459 DI459A DI455 DI455B DI455G
Ventricular arrhythmia DI472 DI472A-EDI472M DI470 DI471
Aortic dissection/aneurism DI710 DI710A DI710B DI711 DI712 DI713 DI715 DI718 DI719
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Appendix 2: ATC codes for redeemed medication 
Anti-
diabetic 
  A10AB A10AC A10AD A10AE A10BA A10BB A10BH A10BX 
            
Betablocker C07AB C07AA C07AB C07AG      
            
Statins  C10AA         
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Appendix 3: ICD-10 diagnoses for the clinical endpoints 
MI DI210
B 
DI211B DI213B DI210A DI213 DI211A DI447 DI446  
 DI219 DI210 DI210A DDI211 DI211A DI214 DI248 DI249 DI256 
          
Cardiac arrest /Ventricular 
fibrillation 
DI460 DI461 DI469 DI490 DI490A DI490B DI490BA DI470A  
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Abstract 
Objectives:  To determine the extent of clinical cardiac related endpoints and mortality among patients with 
non-specific chest pain (NSCP) and an acute contact to the hospital after the implementation of highly sensitive 
troponins and to identify risk factors among these patients during 12 months follow-up. 
Design: A prospective multicentre study. 
Setting: Emergency departments and Cardiology departments in Southern Denmark. 
Subjects: 1027 patients with an acute hospital contact due to chest pain, in whom a   myocardial infarction or 
other obvious reasons for chest pain had been ruled out. Patients were included from September 2014 to June 
2015 and followed for one year.  
Main outcome measures: All-cause mortality and coronary related clinical endpoints (acute myocardial 
infarction, unstable angina, and coronary revascularisation.)  
Results: Clinical cardiac related endpoints during one year were found in 19 patients (1.9%); two (0.2%) had a 
myocardial infarction, four (0.4%) had unstable angina pectoris and 17 (1.7%) underwent coronary 
revascularisation.  All-cause mortality was observed in seven patients (0.7%). Compared to the general 
population the standardised mortality ratio did not differ. The risk factors associated with a clinical endpoint 
were male gender, BMI >25 kg/m2, previous known CAD, hypertension, hypercholesterolemia, diabetes 
mellitus and use of statins. 73% of the composite endpoints occurred in males. The estimated Hazard ratio for a 
cardiac-related clinical event was 4.7 for the male gender. 
Conclusion: The prognosis for NSCP patients is good. The mortality is comparable with the background 
population. Very few endpoints took place during follow up and occurred mainly in males. Gender was an 
important prognostic factor for cardiac-related clinical endpoints. 
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Introduction  
 
Patients with acute chest pain or chest discomfort represent a large proportion of acute referrals to 
emergency departments and cardiology departments. Only 14-17% ends up with the diagnosis of an 
acute myocardial infarction (MI) (1, 2). Even though an MI is excluded, coronary artery disease (CAD) 
may still be present. CAD is associated with 20% of all deaths in Europe (3). Discharge diagnoses after 
admission because of acute chest pain includes different clinical manifestations of CAD (Acute MI, 
unstable angina pectoris (UAP)), other cardiac-related diagnoses (aortic dissection, pulmonary 
embolus), non-cardiac disorders (gastro-oesophageal diseases, lower airway infection, 
musculoskeletal disorders) and non-specific chest pain (NSCP). The latter group is represented by 
patients discharged without a plausible diagnosis explaining the cause of the chest pain. After the 
implementation of high sensitive troponins (hsTn), where the detection limit for MI has been 
lowered, a relative increase in the frequency of acute MI has been observed (4). Furthermore, the 
increased focus on cardiac diseases with primary and secondary prevention seems to have lowered 
the mortality in patients with cardiovascular disease (5-7). While the former groups are well 
described in the literature (8, 9), very little attention has been given to the NSCP group, except that it 
is well known that NSCP patients have frequent contacts to the health care system and high use of 
medication (10). It has been shown that at least 0.6%-0.8% of NSCP patients discharged from 
emergency departments had an adverse major cardiac event within 30 days (11, 12).    
Hence, chest pain evaluation in these departments is thus a professional challenge as the best 
diagnostic and treatment plan is not obvious for the NSCP patients. 
In this multicentre study, we addressed patients discharged from emergency or cardiology 
departments with the diagnosis of NSCP after the implementation of hsTn for routine clinical use. 
The study objectives were first to describe the outcome of NSCP patients in terms of all-cause 
mortality and clinical cardiac-related events during a follow-up period of at least 12 months.  Second, 
we wanted to identify risk factors that may be helpful in predicting the occurrence of clinical 
ischemic events within 12 months of follow-up. 
 
Methods 
Design and settings 
This study was conducted as a prospective multicentre cohort study. Six hospitals in the Region of 
Southern Denmark (Aabenraa Hospital, Sonderborg hospital, Odense University Hospital, Svendborg 
hospital, Vejle Hospital and Kolding Hospital) were involved and contributed with consecutive acutely 
admitted chest pain patients from emergency departments and cardiology departments. All patients 
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were acutely evaluated by a physician based on clinical history, physical examination, ECGs and 
biochemical biomarkers and included hsTn measurements. The criterion of the third universal 
definition of MI was used (13). 
 
Study population 
All patients aged 30-70 years referred to the emergency department or cardiology department and 
with at least one hsTn measurement during the first 24 hours after admission were identified 
through daily screening in the central biochemical database. This database included all biochemical 
laboratory results from all patients in the Region of Southern Denmark. A hsTn T value <14 ng/L or a 
hsTn I value <25 ng/L was required for inclusion. The diagnosis at discharge given by the attending 
physicians were traced for each patient, and in this study patients were considered to have NSCP  if 
any of the following international diagnosis code (ICD 10 codes) were given: DR072 (precordial chest 
pains) , DR073 (other chest pains), DZ034 (observation for myocardial infarction) and  
DZ035(observation for coronary disease).  
A structured interview within 3 days of discharge was completed by telephone calls to each of the 
patients. Patients were excluded from the study if no contact with the patient was established after 3 
calls during different times of the day and week, if they did not understand Danish/English, were 
intoxicated, pregnant, had an obvious other cause for the chest pain/discomfort, or if they had a 
coronary angiography performed during the index admission regardless of the results. Patients were 
also excluded if they declined informed consent to follow-up or if the medical records regarding the 
index admission were not available. 
Patients were prospectively included during a 9 month period from September 2014 to June 2015 
and followed until June 2016. Thus, the patients were followed for at least 12 months or until 
emigration or death. 
 
Material/Data 
The interview was conducted by the first author or one of two nurses, dedicated to this task only. 
The patients were asked to answer standardised questions regarding symptoms at their index 
contact, medical history, and risk factors for cardiovascular disease. The standardised questionnaire 
was validated for inter-observer validity, where 10 questions from the survey regarding the patient's 
medical history were tested in terms of comparability. The agreement was 72% between the 3 
interviewers. 
After the interview, a written informed consent was signed by the patient giving permission to access 
the patient records, in which laboratory results, ECGs, basic essential clinical features, blood 
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pressure, heart rate, respiratory frequency, saturation, temperature and results of echocardiography 
were registered.  
 
Definitions 
 Smoking was registered as package years. 20 cigarettes per day for a year was one package year. 
Hypertension, hypercholesterolemia, and diabetes were self-reported. Family history included 
cardiovascular disease in a first degree relative regardless of age. Statins were defined according to 
ATC code (C10AA) for cholesterol-lowering medication. 
The patient's history of diseases was on ICD diagnoses from previous admissions for up to 10 years 
from index visit Prior CAD included known acute and chronic ischemic heart disease diagnoses up 10 
years before the index visit. Peripheral artery disease included diagnoses codes for intermittent 
claudication and atherosclerotic disease. Ischemic cerebral diseases included apoplexy and transitory 
cerebral ischemia. Supraventricular tachycardia was atrial fibrillation or atrial flutter.  
Data on use of redeemed medication was based on information from Odense Pharmaco- 
epidemiologic Database (14). Lipid-lowering medication was defined as redeemed medication for up 
to 3 months before index admission.  
 
Clinical outcome  
A clinical cardiac related endpoint at 12-month follow-up was present if the patient had suffered one 
or more of the following clinical manifestations:  cardiac death, acute MI, UAP or coronary 
revascularisation. 
Clinical endpoints were obtained from the National Patient Register (15) and from the Civil 
Registration System (16). The main outcome was a composite endpoint consisting of all-cause 
mortality and clinical cardiac related endpoints.  
 
HsTn assays 
The troponin assays used in this study were hsTn I or T with 99th percentile cut-off points. In Odense 
University Hospital the hsTn I was analysed by Abbot Diagnostics Architect with upper reference limit 
of the 99th percentile of 25 ng/L. The 10% coefficient of variation was at 5 ng/L, The decision limit for 
myocardial infarction was set at >= 25 ng/L(17). hsTn T was used in all other participating hospitals 
and was analysed by Roche Diagnostic Elecsys 2010, modular analytics E170, Cobas e411, Cobas 
e601. The 99th percentile cut off value was 14 ng/L with a 10% coefficient variation at 13 ng/L. The 
decision limit for MI was >= 14 ng/L (18). 
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Sample size calculations  
By inclusion of 1 298 patients, the study had a power of 80% and a two-sided confidence interval of 
95% to identify risk factors that occurred 20% more frequent in patients with a clinical endpoint 
compared to patients without a clinical endpoint. We assumed that clinical endpoints in unexposed 
to be 2% and in exposed to be 5%. 
   
Statistics 
 Continuous variables were categorised in categorical subgroups except for age that was reported in 
medians with interquartile ranges. Receiver-operator curves (ROC) were made for each variable to 
identify reasonable cut off points. Categorical variables were reported in frequency and percentages.  
Pearson's chi-square test was used for intergroup comparison of categorical variables. Laboratory 
data that was not obtained were analysed as missing data. 
Patients were followed until the first upcoming clinical endpoint that was shown for the total cohort 
and according to gender. Unadjusted event data was shown as Kaplan Meier plot according to 
gender. The prognostic effect of variables on the clinical endpoints was analysed by univariates cox 
regression. More variables were tested than reported but all significant variables are reported along 
with some clinical relevant non-significant variables.  P value < 0.05 was considered significant.  
From Statistics Denmark we obtained the population number and mortality for the general 
population 30-70 years old in the region of Southern Denmark for 2015. The expected mortality ratio 
for our study population was calculated from this information. The observed mortality ratio in the 
NSCP study population was compared with the expected mortality ration to estimate the 
standardised mortality ratio compared to the general population. 
Data were analysed using STATA version STATA 14.2 0 (StataCorp, College Station, Texas). 
 
Ethics
After a request to the Regional Scientific Ethical Committees for Southern Denmark, no ethical 
clearance was required (confirmed by email 18.03.2014). The study was registered with The Danish 
Data Protection Agency (2008-58-0035 number 1086). The study was approved by the Danish Health 
Authorities j.nr. 3-3013-573/1 allowing access to discharge diagnosis from the charts.  
A written informed consent to access patient records was obtained from the participants. 
 
 
Results 
Among 1 213 eligible patients, 1 027 returned an informed consent and were included. Figure 1 
shows the flowchart for patient inclusion and exclusion. Non-participants consisted of patients that 
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were eligible, and completed the interview, but did not return informed consent for participation. 
Comparison between participants (n=1 027) and non-participants (n=186) showed a significant 
difference in median age of 54 years (IQR: 47:62)) in participants vs 47 years (IQR: 39:56) in non-
participants, p=0.001. Females accounted for568 (55%) of the participants and 90 (48%) of the non-
participants, p=0.081. Two patients left Denmark before the end of the follow-up time.   
Baseline characteristics of the participants are shown in table 1.  Patients with a clinical endpoint 
were significantly older with a median age of 61 (IQR: 47-62), consisted of more men (73%), had a 
Charlson score >=1 and used cholesterol-lowering medication and had more vascular comorbidity at 
baseline than patients who did not experience a clinical endpoint. 
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During 30 days follow-up the all-cause mortality was zero (0%, 95% CI: 0%-0.3%), two had a MI (0.2%, 
95% CI: 0%-0.5%), zero (0%, 95% CI: 0%-0.3%) had UAP and four (0.4%, 95%CI: 0.01%-0.8%) were 
revascularised. The 30 day composite endpoint was experienced by five patients (0.5%, 95%CI: 0.1%-
0.9%). 
 
 
Table 2 lists the clinical endpoints during 12 months follow-up for the total cohort and according to 
gender.  During one year follow up we found that in the total cohort seven patients died (0.7%, 95% 
CI: 0.2%-1.2%).  Compared to the general population the standardised mortality ratio was 1.2 (95% 
CI: 0.5-2.4).  No cardiac related death was observed, 0 (0%, 95% CI: 0%-0.3%) while two (0.2%, 95% 
Table 1: Descriptive baseline characteristics
P-value
n=1027 % n=1001 % n=26 %
Hospital
Aabenraa 164 16 156 15 8 31
Kolding 210 20 206 21 4 15
Odense 318 31 309 31 9 35
Svendborg 180 17 177 18 3 11
Sonderborg 67 7 67 7 0 0
Vejle 88 9 86 8 2 8
Sex
Female 568 55 561 56 7 27
Male 459 45 440 44 19 73
Median age(IQR)/years 54(47-62) 54(47-62) 61(53-66) 0.010
30-39 102 10 102 10 0 0
40-49 247 24 243 24 4 15
50-59 325 32 319 32 6 23
>60 353 34 337 34 16 62
Charlson score
0 783 76 770 77 13 50
≥1 244 24 231 23 13 50
Smoking status
Previous smoker 338 33 334 33 4 15
Current smoker 257 25 243 24 14 54
Never- smoker 432 42 424 43 8 31
Statins 213 21 202 20 11 42 0.006
Cardiovascular comorbidity
Coronary artery disease 166 16 156 16 10 39 0.002
Periphereal artery disease 19 2 16 2 3 12 0.001
Ischemic cerebral disease 49 5 47 5 2 8 0.479
Supraventricular tachycardia 53 5 51 5 2 8 0.554
Table 1 shows the baseline charcteristics. P values for Chi square test between patients with and without a clinical endpoint.
0.002
Total
0.268
0.003
0.020
0.001
Without clinical endpoint With clinical endpoint 
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CI: 0-0.5%) had a MI, four (0.4%, 95% CI: 0.01%-0.1%) experienced UAP and 17 (1.7%; 95% CI 0.9%-
2.4%) patients underwent coronary revascularisation. In total the number of patients with clinical 
cardiac related endpoints during one year follow up was 19 (1.9%; 95% CI 1.0%-2.7%). 
In total, 26 patients had 30 events which made the composite endpoint 26/1027 (2.5%, 95% CI 1.6%-
3.5%).  
Accounting for one year follow up, 19 (73%) of the total composite endpoints occurred in male 
patients. The difference is even more distinct with time, which is demonstrated in the accumulated 
endpoints plot (Figure 2) and further stratified by gender (figure3). Both figures are depicted for the 
total follow up time of 1.4 years.  
 
 
 
 
 
Table 2: Endpoints during 1 year follow up
P-value
n=26 % n=19 % n=7 %
Death 7 0.7(0.2-1.2) 4 0.9 (0.2-1.7) 3 0.5(0-0.5) 0.506
Cardiac related death 0 0.0(0.0-0.3) 0 0.0(0.0-0.7) 0 0.0(0.0-0.5) Not calculate
Myocardial infarction 2 0.2(0.0-0.5) 2 0.4(0-1.0) 0 0(0-0.5) 0.112
Unstable Angina Pectoris 4 0.4(0.0-0.8) 3 0.7(0-1.4) 1 0.2(1.4) 0.214
Revascularisation 17 1.7(0.9-2.4) 13 2.8 (1.3-4.3) 4 0.7 (0.02-1.4) 0.008
Composite endpoint 26 2.5(1.6-3.5) 19 4.1 (2.3-6.0) 7 1.2 (0.3-2.1) 0.003
Total Male Female
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Table 3 shows the hazard ratio (HR) for risk factors and outcome during a follow-up time of one year. 
This table shows HR with the confidence interval for all clinical events, cardiac-related events, and all-
cause mortality. A univariate analysis was conducted. Due to few clinical events, multivariate analysis 
was omitted.   Significant characteristics associated with clinical events were gender, BMI>25 kg/m2, 
Charlson score >1, previous known CAD and combined ischaemic co-morbidity, hypertension, 
hypercholesterolemia, diabetes and use of statins. It was not possible to obtain cholesterol and statin 
values from 15% of the patients. 
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 Table 3: Hazard ratio for exposure variables and endpoints during 1 year of follow up
Characteristics Al l  cl inica l  events Cardiac cl inica l  events Al l -cause morta l i ty
(n=26) (n=19) (n=7)
Female 1 1 1
Male 3.4(1.4-8.1) 4.7(1.6-14.0) 1.7(0.4-7.6)
Age/years
40+ 1 1 omitted
50+ 1.1(0.3-4.0) 1.0(0.3-3.5) 1
60+ 2.8(0.9-8.4) 1.8(0.6-5.6) 5.6(0.7-46.7)
BMI<25 kg/m2 1 1 1
BMI>25 kg/m2 3.0(1.0-7.6) 4.6(1.1-19.7) 1.4(0.3-7.0)
Charlsons  score=0 1 1
Charlsons  score>=1 3.2(1.5-6.9) 1.9(0.7-4.8) 19.5(2.4-162.3)
Smoking
0-12 package years 1 1 1
>12 package years 1.9(0.8-4.3) 2.1(0.8-5.3) 1.6(0.4-7.2)
Alkohol  0-2 U /week 1 1
Alkohol  >2 U/week 0.8(0.4-1.7) 0.9(0.3-2.1) 0.7(0.2-3.1)
Comorbidi ty
Not known coronary artery disease 1 1 1
Coronary artery disease 3.3(1.5-7.3) 3.8(1.5-9.5) 2.1(0.4-11.0)
Not known ischemic cerebra l  disease 1 1 1
Ischemic cerebra l  diease 1.7(0.4-7.0) 1.1(0.2-8.3) 3.4(0.4-27.8)
Not known with extremity i schemia 1 1 1
Ekstremity i schemia 7.4(2.2-24,5) 3.1(0.4-23) 23.5(4.6-121.0)
Not known supraventricular tachycardia 1 1 1
Supraventricular tachycardia 1.5(0.4-6.4) 1.0(0.2-7.6) 3.0(0.4-25.2)
None of the above mentioned comorbidi ty 1 1 1
Combined i schemic comorbidi ty* 4.0(1.9-8.7) 3.6(1.5-8.9) 5.5(1.2-24.4)
Not known hypertens ion 1 1 1
Known  hypertens ion 5.2(2.1-12.8) 5.8(1.9-17.5) 3.9(0.8-20.2)
Not known hypercholesterolemia 1 1 1
Known hypercholesterolemia 2.5(1.1-5.9) 6.0(1.7-20.6) 0.5(0.1-2.5)
Not known diabetes 1 1 1
Known diabetes 5.0(2.2-11.6) 5.2(2.0-13.7) 4.7(0.9-24.1)
No fami ly his tory of CVD 1 1 1
Fami ly his tory of CVD 1.7(0.7-3.8) 1.6(0.6-4.0) 2.3(0.4-11.8)
Triglycerides<1 mmol/L 1 1 1
Triglycerides>=1 mmol/L 1.4(0.5-3.8) 1.0(0.4-2.7) n.c
Tota l  cholesterol<5 mmol/L 1 1 1
Tota l  cholesterol>5 mmol/L 0.5(.2-1.2) 0.4(0.2-1.1) 1.1(0.2-5.2)
LDL<3 mmol/L 1 1 1
LDL>3 mmol/L 0.5(0.2-1.1) 0.3(0.1-1.0) 1.1(0.2-5.4)
HDL>=1 mmol/L 1 1 1
HDL<1 mmol/L 2.1(0.8-5.5) 3.0(1.1-8.5) n.c
No s tatins 1 1 1
Statins 2.8(1.3-6.2) 4.3(1.8-10.6) 0.7 (0.1-5.5)
*Combined ischemic comorbidity consists of coronary artery disease, ischemic cerebral disease and ekstremity ischemia.
n.c: not calculated, CVD: cardiovascular disease, LDL: Low density lipoprotein,  HDL: High density lipoprotein
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Discussion 
Prognosis for NSCP patients 
In general patients with NSCP have gained little attention. However, as shown in this study out of a 
cohort of 4 289 patients with a hsTn measurement in the emergency departments or cardiology 
departments, NSCP patients compose roughly 25% and thereby a substantial and unneglectable 
proportion of the chest pain patients.  
The prognosis for NSCP patients, when it comes to one-year all-cause mortality was 0.7 %, not 
different from the age and gender-adjusted background population. The risk for a clinical cardiac 
related endpoint was 1.9% in 12 months.  
Comparing NSCP patients with the Danish general population from the same demographic area 
during 2015 the standardised mortality rate was 1.2(CI: 0.5-2.4)(19)  without significant difference, 
which confirms the favourable prognosis for NSCP patients.  
 
Fagring et al showed a one-year mortality rate of 0.9% and 1.5 % in respectively women and men 
aged 25-74 years with NSCP in 2006, which was before hsTn (20). This is almost twice as high as the 
mortality rate in our study conducted after the hsTn implementation. 
The results of our study are confirmed by two other studies (11, 12). The first one regardless of 
troponin assay showed that NSCP patients during 30 days follow up had an MI rate of 0.5%, 0.3% 
experienced unplanned revascularisation and 0.2% died during 30 days follow up in NSCP 
Patients(11). 
In a recent population-based study from Sweden, the 30-day mortality for NSCP patients after the 
implementation of hsTn (12) was 0.2%, MI 0.3 %) and revascularisation rate 0.3% for patients directly 
discharged from emergency departments after chest pain. Hence, the prognosis for directly 
discharged patients was much more benign than for the briefly admitted patients, respectively 1.1%, 
5.0% and 4.0% for mortality, MI, and revascularisation within 30 days. Our results were comparable 
with patients directly discharged. These rates are similar to our findings and underline that most 
clinical events occur during early follow-up (12).  
Other studies have looked into the prognosis of patients with excluded MI. Excluded MI also includes 
patients with other cardiac-related diseases and non-cardiac related chest pain. Our results confirm 
previous studies showing a low event rate among patients with a first hsTn below the detection limit 
for acute MI (21-23). Bandstein et al. demonstrated that in a cohort of patients >25 years presenting 
to the ED with chest pain and one hsTn T <14 1.2 % (146/12033) patients experienced an MI during 
one year follow up (22). Even though we looked at overall ischemic heart disease and not just acute 
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MI, our event rate was lower. This could be explained by the age difference between the cohorts 
(24).   
Kelly et al. (23) found in a cohort with chest pain presentation in an ED, normal ECG and normal 
troponins a mortality rate of 3%, MI of 0.6% and revascularization 3.1% during a median follow up 
time of 48 months. The patient group in this sub-study was younger, preselected without previous 
known CAD and consisted of 55% men. Furthermore, the troponin assay used in this study, even 
though with a cutoff point at 99 percentile was a previous generation of troponin assay than the 
hsTn used in our study. Furthermore, this study was a single centre study and could reflect a 
demographic higher risk group in contrast to our multicentre study and that could explain why our 
results differ. 
Comparing the NSCP population with stable CAD patients, several studies have demonstrated a one-
year NSCP annual mortality < 1% (25, 26). These studies in combination with ours, shows that stable 
CAD and NSCP have similar prognosis probably caused by better prevention and treatment strategies 
in CAD patients.  
The prognosis for the NSCP patients regarding clinical manifestations of CAD is good. The few clinical 
events taking place during follow up imply that the risk stratification taking place in the routine 
clinical setting is sufficient. The endpoints shown in this study makes the clinician capable of 
reassuring the patients of their good prognosis and might reduce the re-admission rate for this 
patient group. 
 
Risk factors for future cardiac-related events among the NSCP patients 
This is the first study of our knowledge to assess risk factors in non-specific chest pain patients after 
hsTn implementation. We showed that the risk factors characterizing patients with a one year risk of 
cardiac events are male gender, BMI >25 kg/m2, previous known CAD or other vascular co-morbidity, 
hypertension, hypercholesterolemia, diabetes mellitus and use of statins.  
Omstedt et al (11)  showed that the risk of a future MI, unplanned revascularisation and death in 
NSCP patients is associated with age, previous MI, heart failure, hypertension, stroke, 
hyperlipidemia, diabetes mellitus and male gender. These risk factors were recognised in our study. 
Nejatian et al. study (12)showed that admitted patients had a worse prognosis than the directly 
discharged patients. However, the admitted patients had more cardiovascular risk factors 
demonstrating the clinical assessment is a crucial part of chest pain assessment and even with hsTn, 
a blood test cannot stand alone. Especially in the clinical evaluation of unstable angina, risk profile 
assessment is crucial for further decision making.  
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Strength and limitations 
The strength of our study is that it was a multicentre study with a prospective data collection. All 
outcome data were obtained from national registration systems linked to individual civil registration 
numbers, which results in no loss to follow up (15, 16).  
Our study has a number of limitations. The cohort was selected as all patients with a coronary 
angiography performed during index contact were excluded and we cannot account for the 
endpoints in those patients. We chose to exclude these patients as they were evaluated by a 
physician to be suspected for CAD during index visit since a coronary angiography was performed 
acutely during this visit.  
Our study participation was dependent on the written informed consent. Even though they 
participated in the interview, 186 patients did not return this consent. We do not know the reasons 
for not returning the informed consent. Some of these patients may have been ill, not capable to 
return the consent, hospitalised or they might just not want to participate. 
We only included patients up to 70 years old. We know from previously developed risk models that 
age is an important factor for assessment of cardiovascular risk. This could partially explain the 
differences between our study and other studies describes above as many studies include patients 
above 18 years old (11, 12, 22). Our study cohort consisted of more women than men; however male 
gender is associated with increased risk of a CAD.  An increasing tendency of female among NSCP 
patients has been shown by Fagring et al(20).  Health care systems have during the last couple of 
years conveyed that females show other symptoms than men in relation to heart attack and could 
encourage more females to seek medical attention. 
Nearly 15% of the patients were missing information on their cholesterol levels and this might have 
had an impact on that sub analysis. 
The main limitation is the few events occurring during follow up, which restricted our possibility to 
search for risk factors for the events. A sample size was calculated before study start and based on 
outcome rates from existing literature. However, the calculation was overestimating the outcome 
rate. A larger study cohort would have resulted in more events which would have allowed 
multivariate analysis of the risk factors for adverse outcomes.  
 
This study has shown that the prognosis for NSCP patients is good. Very few patients, who were not 
identified during the index visit, had a clinical endpoint. However, to be able to predict patients at 
risk requires a much larger study due to the few events observed in this patient group. Future 
research could focus on NSCP patients with the identified risk factors from this study.  Future area of 
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research may even focus on how to reduce the frequency of visits from NSCP patients in our 
emergency and cardiology departments. 
 
Conclusion 
Our study demonstrates that the prognosis for patients with NSCP is good. Among NSCP patients 
with cardiac related endpoints, male gender is a significant risk factor for an adverse outcome among 
with BMI >25 kg/m2, previous known CAD or other vascular co-morbidity, hypertension, 
hypercholesterolemia, diabetes mellitus and use of statins. 
Patients who are discharged from the hospital after an initial assessment for acute chest pain and 
without further investigations are evaluated correctly and can be assured of their good prognosis. 
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Abstract 
Objectives: To examine the prevalence of coronary artery calcification and frequency of cardiac 
events in a cohort of non-specific chest pain (NSCP) patients (an acute admission for chest pain and 
discharged without an obvious reason for the chest pain) and compare with the background 
population.  
Design: A double-blinded prospective cohort study examined with non-contrast CT scan and 
measurement of the coronary artery calcium (CAC) score. 
Setting: Departments of Emergency and Cardiology in the Southern Region of Denmark. 
Subjects: The study population consists of 229 NSCP patients and was compared with 722 patients 
from the background population. The patients were included from September 2014 until June 2015 
and followed for a year.  
Main outcomes measures: Prevalence of CAC.  Cardiac-related mortality, acute myocardial infarction 
(MI), ventricular tachycardia (VT), unstable angina (UAP) and coronary revascularisation.  
Results: No significant difference in prevalence of CAC was found. During one year follow-up, two 
(0.9%) NSCP patients were revascularised, while no one died experienced MI, VT or had UAP. In the 
background population, four (0.6%) experienced a clinical endpoint; one cardiac-related death, two 
with MI, one had VT.  
Conclusion: The prevalence of CAC is comparable with the background population, and the prognosis 
for NSCP patients during one-year follow-up is excellent.  
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Introduction 
Cardiovascular disease remains a major public health problem and causes half of all deaths in 
Europe, while coronary artery disease (CAD) accounts for 20% of all deaths in Europe(1). One of five 
patients with chest pain in the emergency departments turns out to fulfill the diagnostic criteria of 
acute myocardial infarction (MI) (2, 3). Other causes of acute chest pain may be of cardiovascular 
origin (aneurysm, aortic dissection pulmonary embolism), but can also be non-cardiac related 
(gastrointestinal disorders, musculoskeletal disorders) while in a significant number of patients the 
cause of symptoms remains unknown, and these patients are defined as having non-Specific Chest 
Pain (NSCP).  
However, even if acute MI is definitely excluded, CAD may be present with an inherent risk of future 
cardiac events. Hence, 0.8% of NSCP patients experienced an adverse outcome during 30 days 
follows up after discharge from an emergency department (4). It has been shown that up to 20% of 
patients with CAD do not have any traditional risk factors such as hypertension, hyperlipidemia, 
diabetes or smoking (5), thus a non-contrast cardiac CT might serve as a tool in risk stratification by 
measuring the presence and extent of coronary artery calcium (CAC). The advantages of non-contrast 
cardiac CT are that the method is easy to perform and interpret, the reproducibility is high and the 
radiation exposure is low (3, 6-8). The role of a non-contrast cardiac CT as a risk stratification tool has 
been established in asymptomatic persons (9). The prevalence of CAC in an asymptomatic 
background population without known prior CVD has been shown to be 44%-50% (10, 11). The Multi-
Ethnic Study of Atherosclerosis (MESA) demonstrated that an increased CAC score was associated 
with a higher risk of CAD during a 10 year follow up period (12). However, the clinical importance of 
CAC in patients with acute chest pain, in whom an acute MI has been ruled out, remains to be 
investigated.  
In order to evaluate the non-contrast cardiac CT as a potential risk stratification tool for patients with 
NSCP, the aim of the present study was twofold. First, we wanted to investigate the prevalence of 
CAC among NSCP patients and to compare the findings with observations from an asymptomatic 
background population. Second, we wished to examine the frequency of clinical cardiac events 
related to CAC in NSCP patients during a 12 months follow-up period, and compare these data with 
the results from the asymptomatic background population but also those directly referred for a 
further cardiac test from index contact.  
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Method and materials 
Study design 
This study was a double-blinded prospective cohort study that included patients from the emergency 
and cardiology departments in the Region of Southern Denmark. All patients with an acute visit for 
chest pain to the hospitals in Odense, Svendborg, Vejle, Kolding, Aabenraa or Sonderborg, and at 
least one troponin measurement during the contact were included. The inclusion period was from 
September 2014 until May 2015. The patients were invited for this study if they were discharged 
without any obvious reason for the chest pain (NSCP diagnosis (ICD codes: 
DR072/DR073/DR034/DR035)).  
 
Study population 
Through the central biochemical laboratory for all hospitals in the region of Southern Denmark, all 
patients with measurement of troponin in the emergency and cardiology departments were 
identified on a daily basis. Electronic patient files were scrutinized in all patients with normal 
troponin values, as defined below.  
Patients had to complete a structured questionnaire by a telephone interview within three days of 
discharge from the index admission.  
Afterwards written information and a consent form for participation were sent to the patient. 
Patients who returned the consent form were scheduled for the CT scan. The participant and the 
physicians were blinded for the result of the non-contrast CT. 
 
The inclusion and exclusion criteria for the study are defined below 
 
Inclusion criteria: 
• Normal troponin (troponin T <14 ng/mL or troponin I< 30 ng/mL)’ 
• Age 30-70 years  
• Known as one risk factor for CAD (hypertension, hypercholesterolemia, familiar disposition, and 
diabetes mellitus, present or former smoker).  
 
Exclusions criteria: 
• Living outside the catchment area of Region of Southern Denmark 
• Refusing participation in the telephone interview and or CT scan 
3 
 
105
• Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and cardiac 
imaging test within the last 5 years 
• Not Danish-speaking, 
 
We used the Danish Risk Score study (DanRisk) population (11) as a control group representing the 
background population. The DanRisk study population consisted of 1 257 asymptomatic subjects 
aged 50 and 60 years old, who in 2009 had been examined in one of four cardiac computed 
tomography  (CT) centres (Odense, Esbjerg, Vejle or Svendborg) in the Region of Southern Denmark. 
The inclusion criteria in this study were at least one risk factor for CAD (hypertension, 
hypercholesterolemia, familiar disposition, known smoker and diabetes mellitus), and exclusion 
criteria were known, CAD. Patients missing CAC were excluded. The patient selection procedure used 
in the DanRisk study is described in details elsewhere (11). 
 
Definitions 
In the NSCP population, comorbidity was self-reported. Diabetes Mellitus was defined as the use of 
antidiabetic medication or a diagnosis given by their general practitioner. Hypertension and 
hypercholesterolemia were present if the patients stated to be in relevant medical treatment or had 
received the diagnoses by the general practitioner. Family history was defined as a first degree 
relative with cardiovascular disease without consideration of age. Smoking was defined as a current 
smoker. Systolic and diastolic blood pressure and heart rate were retrieved from the patient files, as 
the first measured value during the index admission. Cholesterol values were collected up to three 
months before and three months after the index admission. The value closest to the index date was 
used.  BMI was calculated based on self-reported height and weight. 
For the DanRisk subjects in this study Diabetes Mellitus was defined as the use of anti-diabetic 
medication that included any oral antidiabetic drug and/or insulin. Hypertension was defined as the 
use of antihypertensive medical treatment. Antihypertensive therapy included angiotensin-
converting enzyme inhibitors, angiotensin-receptor antagonist, calcium channel blockers, diuretics, 
beta-blockers, alpha-blockers, and centrally acting antihypertensive drugs. Hypercholesterolemia 
was defined as the use of lipid-lowering medication. Family history was defined as first degree 
relative with a cardiovascular disease, male<55 years and female <65 years. Smoking was defined as 
a current smoker. Blood pressure, heart rate, BMI and cholesterol values were measured at baseline 
examination.  
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Troponins 
The troponin assays used for this study were high sensitive troponins with a 99th percentile upper 
reference limit.  
The cardiac troponin I, used by Odense University Hospital, was analyzed by use of the Abbot 
Diagnostics Architect with an upper reference limit of the 99th percentile of 25 ng/L and a coefficient 
of variation < 10% at 5 ng/L. The decision limit for MI was set at >= 25 ng/L 
Troponin T, used by all other participating hospitals, was analysed by Roche Diagnostic Elecsys 2010, 
modular analytics E170, Cobas e411, Cobas e601. The 99th percentile upper reference limit was 14 
ng/L and a coefficient variation <10% at 13 ng/L. The decision limit was set >= 14 ng/L for MI. 
 
Cardiac CT protocol 
CAC was assessed by summing the scores from all foci in the coronary arteries and expressed in 
Agatston unit (AU) (6). CAC was assessed by trained radiographers and reanalyzed by the first author. 
The correlation was 99%.  
Two centres used dual-source CT scanner (SOMATOM Definition Flash, Siemens Healthcare, 
Forchheim, Germany) with prospective ECG triggering. In persons with a heart rate <75 beats/minute 
the ECG triggering was set in diastolic phase at 65-75% of the cardiac R-R interval. In persons with 
heart rate ≥75 beats/min the ECG triggering was set in systolic phase at 250-400 ms. Additional 
settings: slice thickness3 mm, collimation 128 x 0.6 mm, gantry rotation time 0.28ms, 120 kV tube 
voltage, 90mAs/rotation. One centre used a GE 64-slice CT-scanner (Discovery 750 HD; GE 
Healthcare). In persons with a heart rate <75 beats/minute the ECG triggering was set in diastolic 
phase at 75% of the cardiac R-R interval. In persons with heart rate ≥75 beats/min the ECG triggering 
was set in systolic phase at 40% of the cardiac R-R interval. Additional settings: slice thickness 2.5 
mm, collimation 64 x 0.625 mm, gantry rotation time 0.35ms, 120 kV tube voltage and 200 mA tube 
current. The last centre used a Toshiba Aquillion Next Generation CT scanner with prospective ECG 
triggering. If heart rate was <75 bpm the ECG triggering was in the diastole phase at 65%-75% of the 
R-R interval. In persons with heart rates ≥75 beats/min, the ECG triggering was set in systolic phase 
at 40%. Slice Thickness was 0.5 mm, collimation after scan range 0.5 mm x 240 – 320, gantry rotation 
time 0.275 ms and 120 kV tube voltage. 
 
Follow-up 
The study was conducted as a double-blinded study with a 12 month follow-up time. Neither the 
participants nor the investigators knew the results of the CAC score before the end of follow-up. By 
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then the participants and their general practitioner received a letter with the results of the CAC 
score.  
The clinical endpoints in the follow-up study were cardiac death, ventricular tachycardia (VT), non-
fatal MI, coronary revascularization and unstable angina. The endpoints were compared with 
DanRisk participants. Furthermore, we did a comparison with NSCP patients who were referred for 
cardiac imaging testing at the index admission and thus did not participate in our study. These 
patients were referred for further diagnostic testing by the physician on call that evaluated these 
patients to have a higher risk of CAD. 
 
Sample size 
A sample size calculation was performed based on the prevalence of elevated CAC score (CAC>0 AU), 
and we knew that 44% of the background population represented by DanRisk had coronary 
calcifications (CAC>0 AU) (11). In a symptomatic population referred for coronary angiography 79% 
had a CAC>0 AU (13). We assumed in a symptomatic low-risk population, the NSCP group, 62% would 
have CAC>0 AU. The confidence interval was set to 95%, and with an expected power of 80% using 
the Fleiss method gave us a sample size of 238 patients.  
 
Statistical analyses 
Categorical variables were presented as frequency tables and percentages, and continuous variables 
with mean and medians. Fischer's exact test and Chi-square test were used for categorical variables. 
The t-test was used for comparison of normally distributed variables, while the Wilcoxon's rank sum 
test was used for not normally distributed continuous variables. The odds ratio was calculated with 
multi-logistic regression.  
Exclusion analyses (table 1) were performed between participants and non-participants. Non-
participants were those who fulfilled the eligibility criteria but were not recruited. The variables were 
categorical variables and the inference was estimated with Fishers exact and chi-square test. Age was 
non-parametric and reported with medians and inference estimated with Wilcoxon’s rank-sum test.  
Descriptive characteristics of the DanRisk and the NSCP patients (Table 2) consisted of a categorical 
and continuous variable. The characteristics were reported with frequency and means. Statistics 
estimates were conducted with Fishers exact test and Chi-square test for categorical and t-test for 
continuous variables.  
The amount of CAC and its association with risk factors were reported with medians for each risk 
factor in NSCP patients and DanRisk patients (Table 3). P values estimates are based on Wilcoxon’s 
rank-sum test. 
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Comparison between coronary calcification (CAC>0 AU) in NSCP patients and the DanRisk population 
was performed with 2x2 tables and Chi-square test, and the relationship between calcification in the 
NSCP and DanRisk patients adjusted for risk factors that were significant in Table 2. Statistics were 
calculated by multivariate logistic regression on coronary calcification status (CAC=0 AU vs CAC >0 
AU). The analyses were performed with STATA 14.2 0 (StataCorp, College Station, Texas). A P-value 
<0.05 was considered to be significant. 
 Ethics 
The protocol was approved by the Regional Scientific Ethical Committee for Southern Denmark (S-
20140055) and conducted in accordance with the Declaration of Helsinki. The study was registered in 
Clinical.Trial.gov with number NCT02422316. The study was registered with The Danish Data 
Protection Agency (2008-58-0035 nr 1092). Written informed consent was obtained from each 
participant. 
The DanRisk protocol was approved by the Regional Scientific Ethical Committee for Southern 
Denmark (S-20080140) and was conducted in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from each participant. 
 
Results 
In total 4 289 patients aged 30 to 70 years old attended an Emergency or Cardiology Department and 
had at least one troponin measurement done. After exclusion of 3 047 patients (i.e. elevated 
troponin, identified a cause of the chest pain, no consent, see Figure 1), 1 241 were left for study 
eligibility. However, further 800 of these for different reasons (i.e. no risk factors, referred for 
coronary imaging) had to be excluded from participation in a cardiac CT scan examination. Of the 
remaining 441 patients with NSCP 229 patients (participants) accepted the invitation, and to undergo 
cardiac CT scan, while 212 patients (non-participants) either declined the invitation or did not show 
up at the time of cardiac CT-scan. The non-participants represented individuals that were eligible but 
not recruited. The mean age was 52 (IQR 44;60) and 57 (IQR 50;64)) years in participants and in non-
participants, respectively, p=0.001. Significantly more were known with hypercholesterolemia and a 
family history of CVD among participants compared to non-participants. No significant difference was 
found in gender, diabetes, hypertension or smoking status. Table 1 lists the comparison between 
participants and non-participants.  
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Figure 1: Flowchart for the inclusion of the NSCP population 
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Figure 2 shows the inclusion of the patients in the DanRisk study. 1 825 random individuals 50 or 60 
years old were invited for study participation. 1 257 accepted the invitation. In total 535 patients 
were excluded, six did not have a CAC score performed, 16 patients were known with CAD, and 513 
did not fulfill the criteria of having at least one risk factor. In total 722 persons from the Danrisk study 
served as controls for NSCP patients.   
 
Figure 2: Flowchart for DanRisk 
 
Table 1 : Participants and non-participants comparison
P-value*
Characteristics n=229 % n=212 %
Median Age (years/IQR) 57(50-64) 52 (44-60) 0.001
Male 98 43 89 42 0.863
Diabetes mellitus 22 10 10 5 0.048
Hypertension 91 40 70 33 0.143
Hypercholesterolemia 97 42 67 32 0.020
Family history 124 54 93 44 0.031
Smoking 58 25 57 27 0.709
P values compares the proporiotions of participants and non-participants that are known with the specific variable
Participants Non-participants
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Table 2 lists the baseline characteristics of the NSCP patients and the DanRisk patients. Mean age for 
the NSCP population was 57 years and 55 years for DanRisk population (p=0.007). A significantly 
higher proportion of NSCP patients had known hypercholesterolemia and family history of CVD, 
while more participants in DanRisk were smoking. Furthermore, a significant difference between the 
populations regarding blood pressure, heart rate and total cholesterol was found.  
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Table 2: Descriptive characteristics of NSCP and background population.
P-value*
Characteristics n=229 % n=722 %
0.476
Female 131 57 327 55
Male 98 43 295 45
Age 0.001
30-39 7 3 -
40-49 46 20 -
50-59 76 33 316 44
60-70 100 44 406 56
Hospital 0.001
Odense 70 31 175 24
Vejle 63 27 171 24
Aabenraa 58 25 - -
Svendborg 38 17 180 25
Esbjerg - - 196 27
Hypertension 91 40 266 37 0.458
Hypercholesterolemia 97 42 126 18 0.001
Diabetes 22 10 59 8 0.509
Family history 124 54 287 40 0.001
Smoking 58 25 314 44 0.001
Mean Mean
Systolic blood pressure (mmHg) 144 137 0.001
Diastolic blood pressure ( mmHg) 97 83 0.002
Pulse (rate/min) 74 71 0.001
Total cholesterol mmol/L 5.2 5.5 0.005
LDL cholesterol mmol/L 3.1 3.2 0.067
HDL cholesterol mmol/L 1.4 1.5 0.088
BMI (kg/m2) 27 27 0.715
*P va lues  estimates  for comparison of mean va lues
NSCP population Background population
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The median CAC score for each variable is listed in Table 3. A significant difference was found 
between patients ≥ 60 years in the NSCP population and the asymptomatic 60 years old patients in 
DanRisk cohort. Patients with hypertension in the NSCP population also had significantly more CAC 
than hypertensive DanRisk patients.  
 
 
 
The prevalence of CAC score >0 AU was 54 % in the NSCP population and 52 % in the DanRisk cohort 
(p=0.605). When adjusted for sex, age, hypercholesterolemia, smoking status and family history in a 
multi-logistic regression analysis no significant difference was found between the presences of CAC 
in the NSCP population vs the DanRisk cohort (Odds ratio (OR) 1.3 (95%: 0.9-1.9), p=0.126). 
During one year follow-up 2/ 229 (0.9%) NSCP patients were revascularised, while no one died from 
cardiac-related causes, or had an MI, VT or UAP. The two patients with events were a female aged 64 
and a male aged 60 years with a CAC score of 349 AU and 2595 AU, respectively. Both were known as 
hypertension, hypercholesterolemia and a family history of CVD.  Fisher's exact test showed no 
Table 3: Median CAC estimates based on characteristics variable   
NSCP Background population
P-value*
AU AU
Female 0(0;67) 0(0:18) 0.736
Male 18(0;83) 9(0;116) 0.117
Age
30-39 0(0;1)
40-49 0(0;5)
50-59 0(0;33) 0(0;12.5) 0.247
60-70 47(0;147) 7(0;110) 0.008
Hospital
Odense 0(0;26) 1(0;69) 0.019
Vejle 8(0;104) 4(0;28) 0.109
Aabenraa 10(0;120) - -
Svendborg 16(0;65) 0(0;61) 0.083
Esbjerg - 0(0;66) -
Hypertension 30(0;251) 4(0;96) 0.022
Hypercholesterolemia 6(0;94) 14(0;127) 0.878
Diabetes 61(0;253) 11(0;129) 0.251
Familiar history of CVD 3(0;72) 1(0;36) 0.198
Smoking 4(0;133) 5(0;73) 0.607
* P value compares median value of CAC (AU) between NSCP and background population.   
Median CAC (IQR) Median CAC (IQR)
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statistical difference in endpoints p=0.636 between NSCP and DanRisk. The event rate in the DanRisk 
population was 4 /722 (0.6%) one cardiac-related death, two had MI, and one had VT. All four 
patients were males. The patient with VT was 50 years and had a CAC=0, but also a family history of 
CVD. The three other persons in the DanRisk cohort were 60 years old with a CAC score of 166 AU, 
832 AU, and 1326 AU respectively. One was a smoker, one had hypertension and 
hypercholesterolemia, while the last was smoking, had diabetes and a family history of CVD. 
 
 
Table 4 shows how the clinical endpoints are associated with the prevalence of CAC. No significant 
difference was found between the numbers of endpoints related to CAC between the groups.  
211 patients were referred for further work up from the index contact and not included in this study. 
152 went through a cardiac CT, 26 were referred for coronary angiography and 33 for myocardial 
perfusion scintigraphy. The combined clinical endpoints in this study were 11/211 (5.2%). Two 
patients had UAP, two had MI and nine had coronary revascularization performed during one year of 
follow-up. No one had VT or died from cardiac-related causes. Table 5 shows the event rate in those 
referred directly for cardiac testing is significantly higher compared to the background population 
and to the NSCP group.  
 
 
 
 
Table 4 : The distribution of CAC and endpoints for NSCP and background population. 
n %(CI) n %(CI) n %(CI)
NSCP 2/229 0.9(0.2-2.9) 0/106 0(0.0-3.0) 2/123 1.6(0.3-5.3)
Background population 4/722 0.6(0.2-1.3) 1/350 0.3(0.1-1.4) 3/372 0.8(0.2-2.2)
CAC=0 AU CAC>0 AUTotal
Referred for cardiac testing Study population Background population
number (n) 211 229 722
event (n) 11 2 4
% 5.2 0.9 0.6
CI % 2.8-8.9 0.1-2.9 0.2-1.3
Table 5: number of events in the patients referred directly for cardiac testing, 
the study population and Background population.
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Discussion 
This is the first study to our knowledge to evaluate the role of non-contrast CT in a NSCP population.  
We showed that CAC can be detected in roughly half of patients with NSCP, and the occurrence does 
not differ significantly from what can be found in the background population. Furthermore, the CAC 
prevalence and prognosis for NSCP patients does not differ from the prognosis in the asymptomatic 
background population. However comparing NSCP patients and background population with those 
referred for cardiac investigation at index contact showed the latter to have a significantly higher 
rate of clinical events.  Our study demonstrated that results of non-contrast cardiac CT in NSCP 
patients does not differ from the background population, and we thus do not consider the results of 
this examination as a potential stratification tool for NSCP patients compared to use of cardiac CT in 
the background population. The use of cardiac CT scan for CAC appears to be of limited value in the 
setting of patients with NSCP, and will in the worst case scenario lead to more downstream test 
utilization. 
 
Laudon et al. (14) showed that in non-cardiac chest pain patients presenting to the ED and fulfilling 
the criteria for UAP, the prevalence of CAC was 49%, which is consistent with our findings in NSCP 
patients. Non-cardiac chest pain patients, all though excluded for MI, represent a heterogeneous 
group and also include patients with other causes of chest pain than cardiac related. In Laudon’s 
study non-cardiac chest pain patients with a CAC=0 had a 5-year probability of event-free survival of 
100%. This was significantly better than the cardiac-related chest pain group, implying that a non-
contrast CT scan may be useful in the discrimination between non-cardiac related and cardiac related 
chest pain. However, the study by Laudon et al included patients fulfilling the criteria for unstable 
angina, who were scanned during index contact, which makes their patient population a higher risk 
than our patients. NSCP patients in our study were scanned after discharge and exclusion for high-
risk patients that were referred for further investigation at index contact  
The Society of Cardiovascular Computed Tomography Guidelines recommends (15) that patients in 
the emergency department with acute chest pain, a negative ECG, normal biomarkers and low to 
intermediate pretest likelihood by risk stratification and in whom a non-coronary cause of the chest 
pain has been excluded, should be referred for a coronary CT angiography. In the present study we 
found that patients referred for early further workup, had a one-year event rate of 5 %, as opposed 
to the approximately 1 % demonstrated in NSCP patients, who from a clinical point of view did not 
require additional early diagnostic workup. Thus, the current clinical assessment when it comes to 
risk stratification that distinguishes the patients who need further investigations from the NSCP 
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patients seems to be efficient. The differences in characteristics between those referred for further 
investigations and those included in our study (without referral at index contact) is however not 
further elucidated in this study.  
It is not possible to conclude on the prognostic value of CAC in predicting adverse cardiac event due 
to the low number of event in our study, the short follow up time and a small number of participants. 
However, the two patients in the NSCP study population experiencing a clinical event had a high CAC 
score, respectively 349 and 2595, and were known with three risk factors for CVD (hypertension, 
hypercholesterolemia and a family history of CVD). This may suggest a benefit from combining 
traditional risk factors with the presence of severe CAC. In concordance with previous studies that 
found a pooled event rate of 0.3-0.6%/year with CAC=0, the risk of cardiac events is very low when 
CAC=0 (16). In the NSCP population no events among patients with a CAC=0 was observed, while one 
person in DanRisk with CAC=0 experienced VT. 
 
The NSCP population consisted of more patients with hypercholesterolemia vs DanRisk (43% vs 18%). 
We know from previous studies that NSCP is associated with more frequent contacts to the health 
care system and use of medication than the background population (17). This could partially explain 
that more patients in this group could have been diagnosed with hypercholesterolemia. However, 
the higher prevalence of CAC in the NSCP population might be explained by more patients having 
hypercholesterolemia compared to the DanRisk population. The effect of statins on coronary 
calcification has also demonstrated conflicting results with a previous study showing a trend toward 
increasing atheroma calcification with statin use (18).  
 
Strengths /Limitations 
The outcome data collected from the Danish registries are well documented and validated, which 
adds strength to this study (19, 20). The patients included in this study are low-risk patients. It cannot 
be excluded that the participating patients included in this study and DanRisk are healthier as it is 
known that non-participants in clinical trials are at higher risk and have worse outcomes than 
participants (21). NSCP and background population were pre-selected and excluded for known CAD 
and revascularisation or coronary angiography within the last five years, and this excludes the higher 
risk patients. Conversely, both NSCP and DanRisk participants had to have one risk factor for CAD to 
fulfill inclusion criteria excluding very low-risk patients without risk factors. Patients who at index 
admission were referred for further investigations were not included in this study. They could have a 
higher prevalence of CAC which cannot be accounted for in this study.  
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 Age was also a selection criterion in both studies, focusing on 30-70 years old among NSCP patients 
and 50 and 60 years old in DanRisk. Both studies are most useful in evaluating the middle age 
patients. However, we do know that increasing age leads to increased calcification and the use of 
CAC in an older population is hence not useful. The low age among both populations in contrary 
could be a causal explanation for the few events taking place.   
The definitions of risk factors were not similar. Family history was limited by age in the DanRisk study 
while no age limitation existed in NSCP patients, and that could explain the higher proportion of 
patients with family history of CAD among NSCP patients. The data gathering furthermore differed, 
as NSCP patients were acutely admitted and values were extracted from an acute setting, while 
DanRisk patients were investigated in a baseline examination. E.g the blood pressures were not 
obtained uniformly and thus not comparable. 
 
Conclusion 
Based on the results of this study the occurrence of CAC patients with NSCP does not differ 
significantly from what is found in the background population when adjusted for established risk 
factors. Thus, a little more than half of the NSCP patients have detectable CAC on a cardiac CT scan. 
Of notice, the prognosis in these patients is excellent with an overall clinical event rate of less than 
1%. The results of the present study indicate that patients at increased risk of future clinical events 
already are being taken care of during the index hospital contact.  
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Appendices 
Appendix 1: ICD codes diagnoses 
  
  
Chest pain groups Diagnosis ICD codes
MI STEMI DI210B DI211B DI213B DI210A DI213 DI211A DI447 DI446
NSTEMI DI219 DI210 DI210A DDI211 DI211A DI214 DI248 DI249 DI256
Stable AP AP DI201 DI208 DI208D DI209 DI251 DI251B DI208E DI208E1
NSCP NSCP DR073 DR074 DZ035 DR072 DZ034
Other hear related Pulmonal embolus DI260 DI260A DI269 DI269A
 conditions
Cor pulmonale Di279
Pericardial diseases DI318 DI319 DI319A DI313 DI300 DI301A-E DI301 DI308 DI309 DI311
Endocarditis DI330 DI339 DI389
Myocardial disease DI409 DI429 DI428 DI428B DI428A DI420 DI421 DI422 DI426
Mitral valve diseases DI340 DI341
Aortic valve diseases DI350 DI351 DI352 DI358 DI358A DI359 DI442 DI442A DI443 DI443A
Supraventricular Arrythmia DI456C DI471 DI441A-E DI441 DI498 DI499 DI499A DI440 DI480 DI484
DI483 DI482 DI489 DI489A DI489B DI489C DI489D DI481 DI495 DI495B
Block DI446 DI447 DI451 DI451A DI452 DI459 DI459A DI455 DI455B DI455G
Ventricular arrhythmia DI472 DI472A-EDI472M DI470 DI471
Aortic dissection/aneurism DI710 DI710A DI710B DI711 DI712 DI713 DI715 DI718 DI719
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Appendix 2 
The questionnaire used for the phone interview  –translated from Danish to English  
Patients with non-specific chest pain 
-risk stratification and prognosis 
 
The accentuated text is the questions, and the italic is the possible answers  
The patient agrees to participate in the project? 
Yes /No/not participating  
Symptoms 
Did chest pain cause your visit to the hospital? 
Yes/No 
 
How would you describe your chest pain? 
Stinging, Burning, crushing, pressing, other, please specify _______________, Do not know   
Where did you could feel the pain? 
Left breast, Right Breast, behind the sternum, The back, The shoulder blades, Belt-shaped at the chest, The 
right arm, Left arm, The jaw, The stomach, the collarbones, The neck, Other, please specify _____, don't know 
 
What were your symptoms? 
Optional answer 
 
When did your pain start? 
Date/Time 
 
How strong were your pains on a scale from 1-10, when it was at its worst, and where 10 
is the worst pain you can imagine? 
1-10 
 
Did you have other symptoms related to your pain? 
Fatigue, dizziness, shortness of breath, palpitations, Headache, Nausea, cough, Abdominal Pain, No 
other symptoms, other?  
Was the pain constant or intermittent? 
Constant/Intermittent 
 
How did you arrive at the hospital? 
Called the emergency service/Out of hours medical service/Own request/referral by GP/ Other:________________  
What exacerbated the symptoms? 
Physical activity/Cold/mental stress/other 
 
What relieved the symptoms? 
Nitroglycerin/Rest/Oxygen/Other:  
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Previous Angina Pectoris 
Have you previously experienced chest pain 
Yes/No 
 
Have you previously visited a physician due to chest pain? 
Yes/No  
What was the cause of the pain? 
Free text 
 
Have you previously been told you have heart failure or coronary calcification? 
Yes/No  
If yes  
CCS classification 
I: do you have pain with strenuous work? 
II Do you experience chest pain related to fast stair walk and walk? 
III: do you experience chest pain at walking shorter distance than 200 m on regular terrain? 
IV: Do you experience pain at the least activity? 
V: No discomfort at all?  
NYHA classification 
Do you experience dyspnoea in everyday life and how much? 
I: No limitation at all 
II: Normal physical activity gives short breathe 
III: Less strenuous activity gives shortage of breath 
IV: Inconvenience at the least activity, also in rest  
Do you have other heart conditions? 
Yes/no  
Do you have  
Diabetes/ hypertension/ hypercholesterolemia? 
If yes, for how many years  
Other known diseases? 
Optional answer 
 
Did your parents have calcification or thrombus in the heart or brain? 
One parent/both parents/no parents 
 
Are your siblings known with calcification or thrombus? 
Yes/No 
 
How many siblings? 
Optional answer 
 
Are you previous or current smoker? 
Occasional smoker: less than 30 cigarettes in a month. Previous smoker: smoking ended more than a month 
ago. 
Previous/current/never smoker/occasional smoker 
 
How old were you when you started smoking? 
Optional answer 
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How many cigarettes in average do you smoke a day? 
Optional answer 
 
 
How old were you when you quit smoking? 
Optional answer 
 
 
How many items of alcohol in average do you drink per week? 
Optional answer 
 
 
What is your weight? 
Optional answer 
 
 
What is your height? 
Optional answer 
 
 
What do you do for a living? 
Working, pension, flex job, not working, partial sick leave, full-time sick leave, working part-time, student 
 
Describe your job? 
Unskilled worker/shorter higher education/Medium length higher education/Longer higher education/ self-
employed/Vocational education 
 
Have you been referred for further investigation of your heart after your visit? 
Yes /No 
 
Have you previously had any cardiac investigation done like a scan? 
Yes/No 
 
If yes which investigation? 
Optional answer 
 
 
Some of you would be candidates for another study with a non- contrast CT scan. Can I 
send you some information if you are eligible for this study? 
Yes/No   
Can I get access to your patient chart for this study regarding information on admission, 
medication and blood test? 
Yes/No 
 
We also need to written permission to access your chart. I will send you some written 
information and consent to sign. What is your address? 
Optional answer 
 
The reason patient didn’t participate in the study? 
Not at home/Pt not capable to participate/Did not speak Danish/ Phone number was not working/other 
reason. 
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Appendix 3: Chart review  
The accentuated text is the questions, and the italic is the possible answers 
 
Did the patient? 
Fulfil the inclusion criteria 
Have a coronary angiography during admission 
Have an obvious cause of the chest pain 
Been treated for UAP 
Not relevant cause of admission 
Other 
 
What was the cause for the visit? 
Chest pain 
Radiation 
Other?  
Was the patient referred for other examination at the discharge? If so which one? 
Cardiac CT 
Myocardial scintigraphy 
Coronary angiography 
Holter monitoring 
Coronary artery bypass grafting 
Stress test 
Echocardiography 
Outpatient clinic 
Other 
 
Did the patient have an echocardiography during index admission? 
Yes normal EF 
Yes, abnormal EF (<55%) 
No  
Clinical values 
- associated with the index admission. The first measured 
Temperature 
Pulse 
Saturation with and without oxygen 
Respiratory frequency 
Systolic blood pressure 
Diastolic blood pressure  
ECG 
Heart rate on the ECG 
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ECG diagnosis 
Sinus rhythm 
Sinus arrhythmia 
Sinus bradycardia 
Sinus tachycardia 
Supraventricular tachycardia 
ST elevation 
ST depression 
T wave inversion 
Left bundle branch block 
Right bundle branch block 
Ventricular tachycardia 
First degree AV nodal block 
Second or third degree AV nodal block 
Sinus atrial block 
Q waves  
If abnormal ECG:  
ST elevation 
New /previous known/no previous ECG to compare  
ST depression 
New /previous known/no previous ECG to compare 
 
T wave inversion 
New /previous known/no previous ECG to compare  
Bundle branch block 
New /previous known/no previous ECG to compare 
 
Q wave in which derivations? 
Free text  
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